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ABSTRACT 
The two major pathophysiologic mechanisms responsible for 
the development of secondary hyperparathyroidism (SHPT) in 
advanced renal insufficiency are phosphorus retention and low 
levels of 1, 25-dihydroxyvitamin D3 [1,25-(OH) 2D3] . 
The actions of the hormonal form of vitamin D extend 
beyond its role in mineral homeostasis. Recently, analogs of 
vitamin D that are less calcemic, but retain the 
therapeutically useful properties of l,25-(OH)2D have been 
developed. 
This study was designed to determine if a high phosphorus 
diet could be the main contributor for increasing plasma 
phosphate and parathyroid hormone (PTH) and reducing the 
production of renal l,25-(OH)2D3 in renal failure (reduced 
renal cell mass). Another objective was to determine if 
vitamin D analogs could be used as an effective drug in 
lowering plasma PTH and increase calcium during SHPT. 
One hundred twelve 60-day-old male rats of Harlan-Sprague-
Dawley (weighing 400-450 gm) were divided into 7 groups: SLP, 
SHP, NLP, NHP, NHP-A, NHP-B, and NHP-C. SLP and SHP were sham 
(S) operated groups, whereas the rest were unilaterally 
nephrectomized (N). The rats were fed two synthetic diets with 
low (LP) or high (HP) phosphorus levels. Three groups of rats: 
NHP-A, NHP-B, and NHP-C were simultaneously given an oral 
X 
administration of 18 ng/day of l,25-(OH)2D3 (A), 18 ng/day of 
1,25-(0H)2D2 (B) or 2 pig/day of 1,25,28-(OH) 3D2 (C) , 
respectively, every day for 30 days. 
After 30 days all rats were made unconscious with CO2-O2 
(50%:50% vol/vol) and decapitated. Blood samples were 
collected and plasma was analyzed for inorganic phosphorus, 
calcium, 1,25-(OH)2D3, PTH and creatinine. 
The results of this study indicate that sham and 
nephrectomized rats fed the high dietary phosphorus lost 9.50 
and 24.72%, respectively, of their initial body weights. 
Plasma phosphate increased significantly as dietary phosphorus 
increased. The treatment with vitamin D analogs lowered plasma 
phosphate, PTH and raised plasma calcium and 1,25-(OH) 2D3. 
Among the vitamin D analogs used, 1,25-(0H)2D3 was found to be 
superior. These changes indicate that vitamin D analogs may be 
effective in SHPT. 
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INTRODUCTION 
Secondary hyperparathyroidism (SHPT) is a common finding 
in patients with chronic renal failure (Coburn and 
Slatopolsky, 1991; Kubrusly ^  al., 1993). It is caused by 
decreases in the plasma concentration of ionized calcium (Ca^'") 
evoked by recurring increases in the plasma concentration of 
inorganic phosphorus (P^) and phosphorus-mediated suppression 
of renal 25-hydroxyvitamin D-la-hydroxylase (lot-GHase) that 
decreases the plasma concentration of 1,25-dihydroxyvitamin D3 
[1, 25-(OH) 2D3] (Portale ^  al. , 1984). 
Elevated levels of parathyroid hormone (PTH) are now well 
recognized as an important uremic toxin in human medicine. 
Toxic effects of PTH on the brain that bring about depression 
have been studied extensively in the dog (Akmal ^  al., 1984; 
Massry, 1985b). High plasma PTH will slow peripheral nerve 
conduction velocity (Akmal and Massry, 1990). The anemia of 
renal failure is largely related to erythropoietin deficits 
and excess PTH is one of the causes of these deficits and 
contributes to uremic anemia (Massry, 1983). A variety of 
leukocyte malfunctions including failures of the immune 
response have been reported to be caused by excessive PTH in 
uremia (Klinger Bt , 1990) . 
Several reports indicate that PTH causes an increased 
influx of calcium from blood and raises levels of 
2 
intracellular Ca^'^. High cellular calcium activates various 
enzymes that destroy cell membranes, proteins and nucleic 
acids (Fawthrop ^  al., 1991). Therefore, in all sites this 
accumulation of calcium injures mitochondria, disrupting 
energy production, before cells are killed (Nagode , 
1992) . 
A PTH-mediated interference with the response of 
pancreatic insulin-secreting islet cells to a dietary intake 
of glucose appears to be responsible for much of the carbohy­
drate intolerance seen in uremic individuals (Fadda ^  , 
1990) . Thus, the absence of adequate insulin to facilitate 
lowering of blood glucose may be one mechanism of the inap-
petence common in uremia (Nagode et 1992) . 
The relationship between the hyperplastic, hypersecreting 
parathyroid gland and the damaged kidney in the uremic 
patients forms a vicious cycle, as the damaged kidneys can 
produce hypersecretion of PTH (Nagode et , 1992). Because 
renal tubular cells have high concentrations of the receptor 
for PTH, the kidney is affected early in PTH toxicity and 
marked calcium influx into tubular cells causes their death 
(Tan et , 1989) . Later, calcium phosphate precipitating 
within tubular lumen contributes to the renal damage (Lau, 
1989). With loss of more renal tissue, hyperparathyroidism 
(HPT) worsens and the cycle continues (Nagode ^  , 1992) . 
Uremic HPT is usually treated with derivatives of vitamin 
3 
D which can suppress PTH secretion by two mechanisms: 
indirectly through the stimulation of intestinal calcium 
absorption and thereby raising plasma calcium (Brickman ^  
al.. 1974) and directly through actions on PTH gene tran­
scription (Silver ^  , 1985). However, the effectiveness of 
the vitamin D derivatives is limited by the degree to which 
plasma concentrations of calcium can safely be raised (Lee ^  
al., 1994) . There has been considerable interest in ways of 
maximizing the direct, noncalcemic effect on PTH synthesis, 
particularly in use of intermittent injections of high dose of 
vitamin D derivatives (Lee ^  , 1994) . 
The main objectives of this study were to investigate 
whether high phosphorus diets in conjuction with reduced renal 
cell mass (unilateral nephrectomy) are the primary factors 
responsible for increased plasma phosphate and PTH and 
decreased plasma calcium and l,25-(OH)2D3 which are the main 
features of SHPT. Furthermore, 1,25-(OH) jD possesses direct 
suppressive action on PTH synthesis and decreases serum levels 
of PTH in most uremic patients with SHPT. Therefore, attention 
was directed towards determining if some of the vitamin D 
analogs could be used as an effective drug treatment against 
SHPT. 
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REVIEW OF LITERATURE 
Parathyriod Hormone 
Synthesis and secretion 
In the rat, parathyroid glands (PTGs) are a single pair 
embedded in the cranial part of the thyroid glands. They 
possess two types of cells: the chief and the oxyphil cells. 
The chief cells are predominantly involved in the synthesis 
and secretion of PTH (Roth and Raisz, 1966). PTH is a single-
chain polypeptide composed of 84 amino acids with a molecular 
weight of 9500 Daltons (Breslau, 1992). The amino acid 
sequence has been determined in several species and there is a 
high degree of similarity amongst species, particularly in the 
amino-terminal region of the molecule (Habener and Potts, 
1990) . 
The genes for human (Hendy ^  al., 1981), bovine (Gordon 
and Kemper, 1980) , rat (Heinrich et , 1984) , pig (Schmeizer 
et al., 1987) and chicken (Khosla et al., 1988) PTH have all 
been cloned and shown to have two introns and three exons 
(Kronenberg ^  al., 1986). 
The primary RNA transcript transcribed from both the 
introns and exons is processed and translated into PreProPTH 
which is a polypeptide of 115 amino acids with a 
molecular weight of 13000 Daltons. This prehormone is short­
lived, being rapidly cleaved to a smaller peptide, a ProPTH. 
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ProPTH is composed of 90 amino acids and has a molecular 
weight of 10200 Daltons. A second enzymatic cleavage of the 6 
amino acid extension at the amino terminus of the molecule 
results in the final secretory product: 1-84 PTH (Breslau, 
1992) . 
The translational product of the PTH mRNA is PreProPTH, 
which is the precursor of ProPTH. PreProPTH like any other 
proteins that are to be exported from a cell is synthesized on 
ribosomes bound to the rough endoplasmic reticulum. This 
process facilitates its specific transport into the cistern of 
the rough endoplasmic reticulum and directs it along the 
secretory pathway of the cell (Silver and Naveh-Many, 1994) . 
During the synthesis, pre or signal sequence is cleaved from 
the precursor protein and the two amino-terminal methionines 
are removed enzymatically. 
As the nascent chain continues to grow, the hydrophobic 
amino-terminal sequence of PreProPTH emerges and associates 
with the endoplasmic reticulum in accord with the signal 
hypothesis (Von Heijine, 1983). 
A signal peptidase acts enzymatically to cleave the 
glycyl-lysine bond and removes the 23-amino acid signal 
sequence as the protein traverses the membrane of the rough 
endoplasmic reticulum, leaving the intermediate precursor, 
ProPTH, in the lumen of the endoplasmic reticulum (Dorner and 
Kemper, 1978). 
6 
The ProPTH product moves to the Golgi apparatus where the 
dibasic residues at the end of the pro sequence direct the 
enzymatic cleavage of the pro sequence. After synthesis, PTH 
is packed in secretory vesicles and may then be secreted, 
stored or degraded intracellularly. However, since the 
parathyroid cell is not rich in secretory granules, as much as 
90% of the newly generated PTH is neither secreted nor stored 
but proteolytically degraded within the cell (Morrissey ^  
al.. 1980). Furthermore, in the peripheral circulation, the 
intact PTH is cleaved into two major fragments (particularly 
in the liver and probably in the kidney), N-terminal (1-34) 
and C-terminal (53-84). The N-terminal fragment retains all 
the biological activities, whereas the C-terminal has no known 
function (Breslau, 1992). 
Regulations of synthesis and secretion 
Regulation of PTH production is exerted at the stages of 
secretion, intracellular catabolism, transcription and 
proliferation. The secretion of PTH from its secretory 
granules is regulated within seconds to minutes and the major 
regulatory factor is calcium. The regulatioji of PTH gene 
transcription is a major site of PTH regulation which occurs 
within hours and can continue for prolonged periods. The major 
regulators of transcription are 1,25-(OH)2D3, which decreases 
PTH gene transcription and hypocalcemia which increases PTH 
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gene transcription. However, parathyroid cell proliferation is 
the final site of regulation and this occurs after the 
stimulus of prolonged hypocalcemia, but l,25-(OH)2D3 very well 
might have a role in preventing parathyroid cell 
proliferation. However, in vivo this property of l,25-(OH)2D3 
is not established (Silver and Naveh-Many, 1994). 
Rupp ^  aJL. (1990) analyzed the human PTH promoter region 
and identified a number of consensus sites which included a 
sequence resembling cyclic adenosine monophosphate (cAMP) 
responsive element. Demay et aj.. (1990) identified DNA 
sequences in human PTH gene that bind l,25-(OH)2D3 receptor and 
further examined nuclear extracts containing l,25-(OH)2D3 
receptor for the binding to sequences in the 5'-flanking 
region of the human PTH (hPTH) gene. Several reports indicated 
that the transcription of PTH gene is regulated by calcium, 
l,25-(OH)2D3 and estrogen. However, a low extracellular calcium 
concentration is the major secretagogue for PTH and calcium 
was also shown to regulate PTH gene expression both in vitro 
and in vivo. 
Russell ^  (1983) cloned the bovine cDNA for PTH and 
maintained bovine parathyroid cells in primary culture in the 
presence of different calcium concentration. They reported 
that a high calcium concentration (2.5 mM, which in vitro is 
all ionized and therefore equivalent to 5.0 mM in vivo) led to 
a decrease in PTH mRNA levels after 16 hours with a maximum 
effect at 72 hours. However, they indicated that a low calcium 
level has no effect. Brookman ^  (1986) also studied the 
effect of calcium on PTH mRNA levels in primary cultures of 
parathyroid cells. They showed that a low calcium level (0.4 
mM) increased and. that a high calcium (3.0 mM) level decreased 
PTH mRNA levels with a similar time sequences as in Russell et 
al. (1983) . A study conducted by Naveh-Many ^  (1989) in 
rats, showed that small decreases in serum calcium from 2.6 to 
2.1 mM/1 led to large increases in PTH mRNA levels reaching 
three fold that of controls. A high serum calcium had no 
effect on PTH mRNA levels even at concentrations as high as 
6.0 mM/1. 
Thus, physiologically PTH biosynthesis is maximally 
suppressed with respect to calcium, and the gland is geared to 
respond to decreases in serum calcium but not to increases in 
serum calcium. Yamamoto ^  (1989) also studied the in vivo 
effect of calcium on PTH mRNA levels in rats. Their findings 
confirmed that calcium regulated PTH mRNA levels with 
hypocalcemia for 48 hours and their rats with high serum 
calcium (2.9 to 3.4 mM) had the same PTH mRNA levels as those 
with normal serum calcium (2.4 to 2.6 mM) in agreement with 
the results of Naveh-Many ^  a^. (1989). Thus, the in vivo 
results on the effect of calcium on the PTH gene expression 
are obviously the physiologically relevant observation; 
however, the differences between the in vivo and in vitro 
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systems need to be explained. 
In vitro studies with primary cultures of parathyroid 
cells are complicated by the loss of calcium responsiveness 
with time in culture (LeBoff ^  , 1983; MacGregor ^  al. . 
1983) and also because high calcium levels encourage the 
growth of fibroblasts at the expense of parathyroid cells. 
Therefore, studies on the effect of calcium using primary 
cultures of parathyroid cells are only valid at time periods 
when the cells are still responsive to changes in serum 
calcium. 
Sherwood ^  (1968) reported an inverse linear 
relationship between calcium concentration and PTH secretion. 
Mayer et al. (1976) and Mayer and Hurst (1978) found that the 
relationship was sigmoidal and in addition there was a 
nonsuppressible portion of PTH secretion even at very high 
serum calcium levels. Furthermore, Brent ^  (1988) 
confirmed the inverse sigmoidal relationship between PTH and 
serum total and plasma ionized calcium in humans which was 
applicable for rapid and slow changes in serum calcium. 
Johansson ^  al. (1987) measured cytoplasmic calcium 
concentration of single parathyroid cell and have shown a 
sigmoidal relationship between sustained changes in 
cytoplasmic calcium and extracellular calcium concentration in 
the 5 to 3 mM range. The sustained change in calcium concen­
tration is due to the influx of extracellular calcium through 
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calcium channel and perhaps other transduction mechanisms such 
as activation of protein kinase A (PKA) and protein kinase C 
(PKC) (Silver and Naveh-Many, 1994). 
Thus, PTH secretion and perhaps also PTH gene 
transcription might, therefore, respond proportionately to the 
sigmoidal change in cytoplasmic calcium concentration. 
However, Brown (1983) has analyzed in detail the sigmoidal 
relationship between calcium and PTH secretion defining the 
so-called set-point which is the calcium concentration 
producing half of the maximal inhibition of secretion which is 
a useful parameter in the analysis of parathyroid tissue from 
patients with SHPT due to renal failure. It was suggested 
(Brown ^  aJ-, 1982) that there was a shift in the set-point 
to the right indicating a relative insensitivity to calcium. 
In addition, Leboff ^  (1983) and Nygren ^  al. (1988) 
have shown that parathyroid cells in culture, when rapidly 
proliferating, are also relatively insensitive to a high 
calcium showing the importance of rigorously defining in vitro 
conditions for any study on PTH regulation. 
Parathyroid cells have stereospecific, high affinity 
receptors for 1,25-(OH)2D3_ similar to the receptors found in 
the classic target sites for 1,25-(OH)2D3, namely intestine and 
bone (Minghetti and Norman, 1988), and thus the parathyroid is 
a target organ for 1,25-(OH) 2D3. 
Russell ^  (1984) and Silver ^  (1985) 
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demonstrated that addition of l,25-(OH)2D3 and other 
metabolites to bovine parathyroid cells in primary culture 
decreased PTH mRNA levels.to 50% of control at 48 to 96 hours 
with no effect on actin mRNA as a control. Naveh-Many et al. 
(1990) performed nuclear transcript run-off experiments in 
order to determine whether the l,25(OH)2D3 regulation of PTH 
mRNA levels was mediated transcriptionally. They found that 
there was a dramatic reduction in PTH transcription in 1,25-
(OH) 2D3-treated rats to 10% of control rats , whereas jS-actin 
transcription in the same 1,25-(OH) jD^-treated rats was 100% of 
control rats. Therefore, these in vivo results established 
that 1,25-(0H)2D3 regulates PTH mRNA levels through its effect 
on PTH gene transcription and that the parathyroid cell is an 
important target organ for l,25-(OH)2D3 (Silver and Naveh-Many, 
1994) . 
Naveh-Many ^  al. (1990) injected l,25-(OH)2D3 in rats and 
measured the levels of the vitamin D receptor (VDR) mRNA and 
PTH mRNA in parathyroid tissue. They showed that l,25-(OH)2D3 
in physiologically relevant doses led to an increase in VDR 
mRNA levels in the PTGs in contrast to the decrease in the PTH 
mRNA levels. Therefore, l,25-(OH)2D3 increases the expression 
of its receptor's gene in the PTG which would result in 
increased VDR protein synthesis and increased binding of 1,25-
(OH)2D3. This ligand-dependent receptor up-regulation would 
lead to an amplified effect of l,25-(OH)2D3 on the PTH gene and 
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might help explain the dramatic effect of l,25-(OH)2D3 on the 
PTH gene (Silver and Naveh-Many, 1994). 
In summary, Ca^* and 1,25-(OH)jD are the major controllers 
of PTH synthesis and secretion. It is believed that calcium 
mainly controls the secretion of PTH whereas, 1,25-(OH) jD 
regulates the PTH gene transcription. 
Physiological actions 
PTH acts on bone and kidney to maintain plasma levels of 
Ca^'' and decreasing circulating concentrations of phosphate. 
PTH regulates the levels of calcium and phosphate in blood by 
modulating the activities of specific cells in bone and kidney 
(Hadley, 1992). PTH stimulates: 1) the release of calcium and 
phosphate from bone; 2) reabsorption of calcium and phosphate 
from glomerular filtrate and 3) the renal synthesis of 1,25-
(0H)2D3, thereby increasing intestinal absorption of calcium 
and phosphate. Thus, the net result of these actions is to 
raise the level of blood calcium and lower the level of blood 
phosphate (Breslau, 1992; Hadley, 1992). 
However, blood calcium, in turn, is the major regulator of 
PTH secretion and rise in blood calcium decreases PTH 
secretion. Thus, the mutual regulatory interactions of PTH and 
calcium serve to keep the blood level of calcium constant, 
despite moderate fluctuations in diet, bone metabolism and 
renal function (Kronenberg, 1993). 
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PTH has a complex and still poorly understood action on 
bone. Even though PTH causes a release of phosphate from bone, 
PTH administration leads to a fall in the blood levels of 
phosphate, because of the phosphaturia caused by PTH. This 
phosphaturia reinforces the effect of PTH on bone, because low 
levels of blood phosphate independently lead to resorption of 
bone (Hadley, 1992). Phosphate is normally reabsorbed from 
glomerular filtrate both in the proximal and distal convoluted 
tubules. However, reabsorption at both these sites is 
inhibited by PTH (Bringhurst ^  , 1989) . 
PTH and vitamin D interact in a number of complex ways. In 
the kidney, PTH activates la-OHase, which in the proximal 
convoluted tubule catalyzes the synthesis of the most active 
metabolite of vitamin D, 1,25-(OH) 2D3, which, in turn, is a 
potent inducer of intestinal calcium absorption (Garabedian et 
al.. 1972; Kronenberg, 1993). 
In the proximal convoluted cell of the kidney, phosphate 
is transported into the cell against an electrochemical 
gradient. The ATP used to accomplish this task does so 
indirectly; ATP fuels the sodium pump, which drives sodium 
from the cell. Sodium then travels back into the cell in 
response to the concentration gradient established by the 
sodium pump and phosphate transport is coupled to the entry of 
sodium back into the cell (Cheng and Sacktor, 1981) . However, 
PTH blocks this sodium-dependent phosphate cotransport 
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(Kronenberg, 1993). 
In the distal tubule, presumably PTH has a similar effect 
on phosphate transport and stimulates calcium reabsorption 
against an electrochemical gradient (Cheng and Sacktor, 1981). 
Molecular mechanisms 
Bone and kidney are the two target organs of PTH. However, 
while there is a PTH receptor in the osteoblast, there is no 
known PTH receptor in the osteoclast. Intact PTH does not act 
directly in the cytoplasm of its target cells but binds to 
specific receptors on the surface of target cells. This 
binding triggers the release of cytoplasmic second messenger 
that then mediates the multiple distal effects of PTH. 
However, binding of PTH to its receptors requires only the 
first 34 residues of the PTH molecule which contains 84 amino 
acids (Hadley, 1992). 
Recently, several reports have identified new mechanisms 
for the generation of intracellular signals by the PTH 
receptor. However, these reports indicated the existence of 
multiple forms of the PTH receptor (Breslau, 1992). 
But, Hadley (1992) proposed a two-receptor model of PTH 
which each leads to activation of phospholipase C (PLC) or 
adenylate cyclase (AC) although a one-receptor model with 
coupling through different types of G proteins to various 
effector elements has not been excluded (Caulfield and 
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Rosenblatt, 1990; Dunlay and Hruska, 1990). 
The best described pathway so far is the PTH activation of 
PLC. According to this model, the PTH receptor is coupled via 
a G protein to PLC. Binding of PTH to its receptor leads to 
activation of PLC with the subsequent hydrolysis of 
phosphatidylinositol,4,5-bisphosphate (PIP2) to inositol 
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 
generation leads to the release of intracellular calcium 
stores, which produces an increase in the intracellular 
calcium concentration. DAG activates PKC. Both IP3 metabolites 
and PKC may play a role in returning the intracellular calcium 
concentration back to base line, by stimulating the movement 
of calcium from the intracellular to the extracellular 
compartments and by sequestering calcium within intracellular 
organelles (Meltzer ^  al., 1982; Yamaguchi et 1987; 
About-Samra ^  , 1989; Hadley, 1992) . 
The other equally important pathway is PTH activation of 
AC which leads to the generation of cAMP. The cAMP produced by 
AC then binds to the regulatory subunit of PKA. The free 
catalytic subunit then phosphorylates specific serine and 
threonine residues in target proteins (Hadley, 1992; Breslau, 
1992; Kronenberg, 1993). 
In summary, various reports have shown that PTH is capable 
of stimulating both AC and PLC signal transduction pathways to 
manipulate several physiological changes in its target 
tissues. 
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Vitamin D Metabolism and Mechanisms of Actions 
Vitamin D metabolism 
The importance of vitamin D in cellular physiology was 
realized early in medical history from clinical studies on 
rickets (Lowe al•/ 1992). 
Vitamin D is a a prohormone that becomes a required 
nutrient only in the absence of adequate exposure to sunlight 
(Reinhardt et , 1988) , and it is one of the principal 
factors required for normal calcium and phosphorus homeostasis 
as well as for the proper development and maintenance of bone 
(Norman and Henry, 1993; MacDonald ^  al., 1994) . 
Vitamin D is a seco-steroid in which the B ring structure 
is cleaved (Walters, 1992). Exposure of the skin to the 
ultraviolet radiation present in sunlight converts 7-dehy-
drocholesterol to previtamin D3 and this previtamin isomerizes 
to vitamin D3, at body temperature and is transported to the 
liver for further metabolism (Reinhardt et al., 1988). 
However, dietary vitamin D2 and D3 are absorbed in the small 
intestine, where they enter the lymphatic circulation (Rein­
hardt et , 1988) . 
In the liver, the enzyme 25-hydroxylase (25-OHase) 
converts the vitamin to the inactive hormonal precursor 25-
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hydroxyvitamin D (25-OHD) (Walters, 1992), which is the major 
circulating form of vitamin D (Reinhardt ^  al., 1988) . 
Vitamin D and its metabolites circulate in the blood 
primarily bound to and in equilibrium association with the 
vitamin D-binding protein (DBP) that contains a single, high 
affinity, vitamin D specific binding site (Reinhardt ^  , 
1988; Walters, 1992). With the normal concentration of the 
binding protein in plasma, less than 10% of the available 
binding sites usually are occupied (Fraser, 1980) . 
Thus, 25-OHD is transported in the blood bound to DBP and 
taken up by the kidney, where it can be metabolized further to 
more than 30 known metabolites (Horst, 1986; Reinhardt et al.. 
1988) . 
25-OHD is iQf-hydroxylated exclusively in the kidney by the 
renal la-OHase to the biologically active form, 1,25-(OH) jD 
(Walters, 1992) , and regulated through a variety of factors by 
the need for calcium and phosphorus (Reinhardt ^  aJ., 1988). 
Thus, both hydroxylases are cytochrome P^so containing enzymes 
and Icx-OHase activity is tightly controlled by a number of 
ionic and endocrine factors including stimulation by PTH and 
reduced plasma Ca^" or inhibition by 1,25-(OH) jD in a classic 
negative feedback loop (Walters, 1992; Norman and Henry, 
1993). 
Under conditions of adequate plasma Ca^'' levels, 25-OHD is 
alternatively converted to 24,25-(OH) 2D by the reciprocally 
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regulated renal P450 dependent 24-hydroxylase (24-OHase) enzyme 
(Walters, 1992; Norman and Henry, 1993). Furthermore, Brommage 
and DeLuca (1985) and Haussler ^  (1988) indicated that 
24-hydroxylation is the first in a series of steps leading to 
the inactivation of 1,25-(OH)jD and important for the 
elimination of 25-OHD. Thus,the circulating level of 1,25-
(0H)2D is dependent not only on the rate of formation of this 
hormone, but also on the rate of 1,25-(OH) 2D degradation 
(Reinhardt ^  al., 1988; Goff ^  al., 1992). 
1,25-(OH) jD can be cleared from the circulation by biliary 
excretion as polar glucuronide and sulfated metabolites of 
1,25-(0H)2D (Kumar, 1984) and by C-23/C-24 side chain 
oxidation (Lohnes and Jones, 1987; Goff et al., 1992). Thus, 
raising the blood 1,25-(OH)2D concentration by treatment of 
animals with large doses of 1,25-(OH)2D rapidly induces 24-
OHase in many tissues including the kidney 
and intestine (Goff ^  al., 1992). 
Boyle ^  (1971) found out that the in vivo production 
of 1,25-(OH)2D to be related to the concentration of calcium 
in the medium and Omdahl and DeLuca (1977) reported that an 
increased plasma 1,25-(OH)2D concentrations occur in response 
to a low calcium diet. 
However, removal of the parathyroid glands prevents the 
increase of 1,25-(OH)jD in response to low calcium diet and 
calcium may act indirectly via PTH to control production of 
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1,25-(0H)2D (Garabedian ^  al., 1972) . Other reports indicate 
that PTH increases the lor-OHase activity by a cAMP mediated 
mechanism (Fraser and Kodicek, 1973; Horiuchi ^  al., 1977; 
Reinhardt ^  , 1988; Walters, 1992). 
Goff ^  al. (1992) reported that phosphorus deficiency 
seems to prevent the up-regulation by 1,25-(OH)jD of 24-OHase 
activity in the intestine. 
Hypophosphatemia increases 1,25-(OH)2D levels, even in 
parathyroidectomized animals (Tanaka et , 1973; Hughes ^  
al.. 1975; Steele ^  , 1975). Furthermore, Baxter and 
DeLuca (1976) found a low phosphorus diet increased la-OHase 
activity in chickens. The stimulatory ability of the low 
phosphorus diet, however, was small compared to that of the 
low calcium diet. In contrast, Edelstein ^  (1978) found a 
decrease in plasma 1,25-(OH) jD concentration in rats fed low 
phosphorus diet. Thus, there may be differences among species 
in the ability of a low phosphorus diet to stimulate 1,25-
(0H)2D production. Reports by Ribovich and DeLuca (1978) and 
Summerville et. al. (1978) suggest that low phosphorus diet fed 
to rats may stimulate the intestinal accumulation of already 
existing 1,25-(OH) jD presumably by inducing VDRs. 
Once calcium and phosphorus needs have been met, as 
reflected by plasma calcium and phosphate concentrations, 
inhibition of the la-OHase will occur probably through 1,25-
(0H)2D. Thus, Omdahl et al. (1980) indicated that 1,25-(0H)2D 
20 
acts by controlling the synthesis and turnover of the lor-
OHase, in addition to modulating the enzymes endogenous 
activity. Haussler ^  a^.. (1980) demonstrated specific binding 
of 1,25-(OH)jD in chick parathyroid glands as well as in rat 
pituitary glands. 
Thus, these studies suggest that the possibility of 
feedback regulation mechanisms similar to that of many steroid 
hormones that involve the pituitary gland. 
Target organs 
The 1,25-(OH) jD hormone participates in stringent 
regulatory system that governs mineral homeostasis, primarily 
through coordinating actions at several mineral regulating 
organs (MacDonald ^  al., 1994). 
The classical target organs of the hormone are intestine 
bone, kidney, and parathyroid gland. Since the functions of 
1,25-(OH)2D hormone extends beyond mineral homeostasis, there 
are several non-classical target organs. 
Lowe et (1992) have compiled lists of vitamin D target 
organs. Although tissue responsiveness to steroid hormones, 
such as 1,25-(OH)jD, is dependent on the concentration of the 
1,25-(OH) 2D in the extra- and intracellular milieu (Reinhardt 
and Horst, 1989; Goff ^  ^. / 1992), target tissues of 1,25-
(OHjjD must have three key components in order for their genes 
to be regulated by a steroid hormone such as 1,25-(OH) jD 
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(Norman and Henry 1993). These include: 1) a protein receptor 
for the 1,25-(OH) 2D that contains both a unique binding domain 
for 1,25-(OH) jD and a DNA binding domain that allows the 
occupied receptor to locate the genes in the nucleus of the 
cell it regulates, 2) hormone responsive element (HRE) that 
consists of specific sequences of DNA nucleotides that 
facilitate/promote an interaction between the occupied 
receptor and the genes to be regulated (either upward or 
downward) in that particular cell, and 3) access to 1,25-
(0H)2D (usually the hozmone is delivered through blood bound 
to DBP) 
Vitamin D receptor 
The steroid hormone 1,25-(OH) 2D exerts its biological 
actions in target tissues via interactions with specific high 
affinity intracellular receptors (Haussler, 1986; Lowe ^  al.. 
1992) . 
Evidence has been presented for a soluble factor of 
approximately 50 to 70 kDa that interacts with the intestinal 
metabolite of vitamin D in a saturable fashion (Haussler and 
Norman, 1969). Several studies (Lawson ^  ai-, 1971; Holick et 
al.. 1971; Brumbaugh and Haussler, 1975) have shown that this 
soluble factor facilitated l,25-(OH)2D association with 
chromatin. Further evidence for the involvement of functional 
receptors in 1,25-(OH) jD action was demonstrated in clinical 
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studies by Pike ^  al. (1984). These studies provided the 
scientific foundation and the first biochemical evidence for 
the VDR, the hormone receptor that mediates most of the 
biological actions of vitamin D (Lowe ^  , 1992; Walters, 
1992; Norman and Henry, 1993; MacDonald ^  al., 1994; Brown ^  
al., 1994). 
It is clear that VDR functions as a ligand induced 
transcription factor in mediating the genomic effects of 1,25-
(OlDzD. It does so by interacting with specific DNA sequence 
elements or vitamin D responsive elements (VDREs) within 
vitamin D responsive genes in important target tissue such as 
bone, intestine, parathyroid gland and kidney (MacDonald et 
al., 1994). 
Important functional domains of the VDR have been 
identified including regions involved in DNA 
binding, hormone binding, phosphorylation and protein-protein 
interactions (MacDonald et al., 1994). Further evidence 
indicates that VDR heterodimerization with other nuclear 
factors is required for DNA interaction and VDR mediated 
transcription. Thus, the VDR could be dissected into two 
discrete, functionally independent subdivisions: one involved 
in DNA interaction and another in binding the 1,25-(OH) jD 
ligands (Allegretto ^  , 1987; MacDonald ^  al. , 1994) . 
The precise location of the VDR gene within human and rat 
genomes has been determined (MacDonald et , 1994). Southern 
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blot analysis of DNA from human-Chinese hamster cell hybrids 
localized the VDR gene to human chromosome 12 (Paraco ^  , 
1989). This was later extended to 12q by means of somatic cell 
hybrid mapping (Szpirer ^  ^. / 1991) and further refined to 
the 12q 13-14 region with in situ hybridization and linkage 
analysis (Labuda ^  al., 1992). Similarly, the VDR sequence 
was localized to chromosome 7 of the rat genome (Szpirer ^  
al., 1991). In both the human and rat genomes, the VDR gene is 
located within regions where distantly related DNA binding 
proteins also map, including transcription factor SP-1 and the 
gamma isoform of the retinoic acid receptor (RAR) (Ishikawa et 
al.. 1990; Szpirer et al., 1991; Mattei ^  al-, 1991) . This 
clustering of related DNA binding proteins may not be purely 
by chance, and their close proximity might suggest that these 
proteins were derived from some common ancestral gene 
(MacDonald et , 1994) . 
Biological mechanisms of vitamin D 
Historically, over the past two decades much research has 
documented the extensive involvement of 1,25-(OH) 2D in 
generating biological responses via genomic pathways involving 
the nuclear receptors (Pike, 1991). 
Recently, however, evidence has emerged that 1,25-{0H)2D 
may also have the capability to generate biological responses 
via activation of voltage-dependent Ca^'' channels that are 
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coupled via appropriate signal transduction pathways to the 
generation of biological responses (Caffrey and Farach-Carson, 
1989; de Boland ^  li-, 1990). 
Like any steroid hormone 1,25-(OH)aD binds to a specific 
cytosolic receptor in the intestine (Reinhardt ^  , 1984; 
Reinhardt and Horst, 1989; Goff ^  , 1990; Goff et al.. 
1993; Beckman ^  , 1994). The hormone-receptor complex then 
is transported to the nucleus, associates with the chromatin, 
and results in the ^  novo production of mRNA for calcium 
binding protein (CaBP) (Walters, 1992; Lowe ^  al., 1992). 
However, given the unexpectedly widespread distribution of 
VDRs and the well known effects of 1,25-(OH) 2D on Ca^ '' 
translocation in intestine, Walters (1992) developed the 
hypothesis that 1,25-(OH)jD and its receptor regulate 
intracellular calcium homeostasis and, thus, play a role in 
regulating the specialized intracellular effects of calcium. 
These postulated effects of 1,25-(0H)2D could occur by direct 
regulation of cellular calcium levels (by effects at the cell 
membrane), by affecting calcium sequestration/release cycles 
in endoplasmic reticulum or other organelles by affecting 
CaBPs by indirect effects modulating the functions of hormones 
and other agonists which act via membrane receptors, or by 
other unknown mechanisms (Walters, 1992). 
The above hypothesis was tested directly by investigating 
1,25-(OH) jD effect on net ^^Ca^'' uptake in isolated or cultured 
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cells as reviewed by Walters (1992) and reported by Walters ^  
al. (1987) in adult rat ventricular cardiac muscle, in TM4 
mouse Sertoli cells by Akerstorm and Walters (1992), in chick 
embryo myoblast by de Boland and Boland (1985) and in mouse 
mammary gland by Mezzetti et a^.. (1988) . These reports 
indicate that in spite of distinct differences in the pattern 
of 1,25-(OH) 2D induction of -uptake across tissues, these 
studies are important in establishing biological effects of 
the hormone in these tissues and in providing evidence in 
support of the general hypothesis that 1,25-(OH)2D regulates 
intracellular calcium homeostasis (Walters, 1992). 
Several reports (reviewed by Nemere and Norman, 1991) 
described 1,25-(OH) aD-mediated effects in opening calcium 
channels in several tissues. This apparent rapid response 
seems to be linked to activation of PKC and may occur through 
nongenomic mechanisms. However, Walters (1992) reported that 
there are at least two Ca^^-related phenomena: a rapid 1,25-
(OH) 2D mobilization of Ca^'' which serves as a signal 
transduction event and the ultimate and sustained 1,25-(OH) 2D 
effect on the cell which would involve net transcellular Ca^" 
translocation in intestinal (and other epithelial) cells and 
altered intracellular Ca^* homeostasis in symmetrical cells. 
Further studies demonstrated that the mechanism of the 
1,25-(OH)2D enhanced calcium entry involved modulation of 
dihydropyridine sensitive L type Ca^ channels and activation 
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of the Na.*/Ca.^* exchange pathways. However, this effect 
required protein synthesis (Russell ^  al., 1990). 
Although not as thoroughly investigated as effects on 
calcium transport, 1,25-(OH)2D also stimulates phosphate 
translocation in intestine (Marx ^  a^,. / 1983; Karsenty ^  
al.. 1985; Cross and Peterlik, 1988), kidney (Kumar, 1986; 
Kurnik ^  al., 1987) . This phenomena has been briefly 
investigated in two non-classical systems in which l,25-(OH)2D 
has been shown to increase phosphate uptake in skeletal muscle 
and cultured myoblasts and in seminiferous tubules 
(Eliaschewitz ^  , 1982; Teresita and Ricardo, 1991). 
However, in cultured chick embryonic myoblasts the effect of 
1,25-(OH) 2D involved the Na^'-linked phosphate uptake component 
and required protein and RNA synthesis (Teresita and Ricardo, 
1991). 
Several reports indicate that 1,25-(OH) 2D markedly 
increases the levels of one of several vitamin D regulated 
CaBPs in its classical tissues (Walters, 1992). The CaBP-Ds 
thus induced include the CaBP-DjgK in kidney and in chicken 
intestine (Heizmann and Hunziker, 1990; Gross and Kumar, 
1990), CaBP-Dgfc in mammalian intestine (Christakos et al., 
1989; Gross and Kumar, 1990), a paralbumin-like CaBPi2k in 
mammalian skin (Schelling ^  al•/ 1987), now termed epidermal 
CaBP (Rizk-Rabin and Pavlovitch, 1988) , the 6 kDa vitamin K-
dependent bone gla protein known as osteocalcin (Walters, 
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1992), and a 20 kDa integral membrane protein found initially 
in rat intestinal brush border (Kowarski ^  # 1987). 
Because of the heterogeneity of known CaBP-Ds and the lack 
of vitamin D-dependent CaBPs in some 1,25-(OH)jD target 
tissues there is not an obligatory relationship between 1,25-
(0H)2D effects and CaBP induction (Walters ^  , 1991) . 
Although, vitamin D-induced CaBPs may not be present in all 
1,25-(OH) aD targets, vitamin D related CaBPs are present in 
numerous tissues. Their distribution does not necessarily 
correlate with the presence of VDRs, and they are not always 
vitamin D regulated. 
In fact, numerous factors such as age and development, Ca^'' 
and phosphate levels, sex steroids and glucocorticoids are now 
known to participate in CaBP-D regulation (Varghese et al.. 
1988) . Moreover, Christakos ^  (1989) , reviewed that 
levels of the CaBPs are altered in several non-vitamin D 
related disease states. 
Thus, taken collectively, these results further support 
the concept that these interesting proteins may serve 
functions other than simply mediating vitamin D effects. 
However, several investigators have noted the close 
relationship between CaBPnasK intestinal Ca^'' transport and 
further concluded that CaBPosaK CaBP^jK play a role in 1,25-
(OH) jD-induced transport and/or a role in buffering 
intracellular calcium pools during these events (Feher, 1983; 
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Bronner and Stein, 1988; Bronner, 1989 and 1990). 
In the intestine, l,25-(OH)2D stimulation of calcium 
translocation involves, in part, stimulation of the epithelial 
cell Ca-Mg-ATPase (Ghijsen and Van Os, 1982; Zelinki et al., 
1991). Although the enhanced activity may be due in part to 
binding and activation by the CaBP-Ds, recent evidence 
suggests a role for 1,25-(OH) jD in regulating mRNA levels for 
this protein (Zelinski ^  , 1991) . Moreover, there seem to 
be correlations between the cellular locations and magnitude 
of activation of Ca-ATPase and the site and induction of Ca 
transport in intestine and kidney (Gross and Kumar, 1990) . 
Although this response has not yet received a great deal 
of attention in nontraditional targets, 1,25-(OH)jD has been 
shown to increase Ca ATPase activity in isolated cartilage 
cells (Lidor and Edelstein, 1987), and in vascular smooth 
muscle cells (Kawashima, 1988). 
Alkaline phosphatase activity consists of at least three 
glycoprotein isozymes predominantly located in plasma 
membranes of entrocytes, nephron and osteoblasts (McKenna ^  
al. . 1979) . The activity of these enzymes is thought to 
correlate with calcium and phosphate metabolism and their 
levels are considered to reflect osteoblast activity and bone 
turnover (Duda ^  ai., 1988; Nagata ai-, 1989; Fukayama and 
Tashjian, 1990). 
In addition to the description of possible interactions 
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between the CaBP-Ds and alkaline phosphatases, 1,25-(OH)jD 
treatment has been shown to increase alkaline phosphatase 
activity in intestinal epithelial cells and osteoblasts 
(Leathers and Norman, 1985). However, blockade of alkaline 
phosphatase response does not abolish the response of the 
intestinal brush border calcium transport to 1,25-(OH) jD 
(Gross and Kumar, 1990) . 
Alkaline phosphatase regulation by 1,25-(OH)aD has been 
reported in colonic carcinoma cells (Giuliano and Wood, 1991), 
chondrocytes (Schwartz ^  al•, 1988), breast cancer cells 
(Mulkins and Sussman, 1987), and uterine endometrial cells 
(Lieberherr ^  , 1984) . However, studies in the breast 
cancer cells demonstrated that treatment with 1,25-(OH) jD 
increased the levels of the alkaline phosphatase isozymes 
found in normal breast tissue (the bone, liver, kidney form) 
but decreased the activity of the embiyonic isozyme (Mulkins 
and Sussman, 1987). 
The other important biological mechanism of 1,25-(OH) jD is 
the control of its own receptor (Reinhardt and Horst, 1989; 
Goff ^  , 1990) . Binding of the 1,25-(OH) jD-VDR complex to 
DNA regulatory sites results in control of transcription of 
various gene products (Minghetti and Norman, 1988; Goff et 
al., 1990) and regulation of VDR number is an important 
mechanism for modulating cellular responsiveness to 1,25-
{0H)2D as the biological activity of l,25-(OH)2D in cells has 
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shown to be proportional to cell VDR number (Dokoh ^  al.. 
1984; Chen ^  ^. / 1986; Reinhardt and Horst, 1989; Goff ^  
al., 1990) . 
Several hormones (retinoic acid, glucocorticoid and 
estrogen), various physiological states (age, pregnancy and 
lactation), and dietary calcium restriction have been shown to 
alter tissue VDR number, thus, modulating tissue 
responsiveness to l,25-(OH)2D (Reinhardt and Horst, 1989; Goff 
et al., 1990). In addition to stimulating the synthesis of 
VDR, 1,25-(OH) jD also stimulates the synthesis of enzymes 
responsible for 1,25-(OH) 2D inactivation (Reinhardt and Horst, 
1989). Thus, report by Reinhardt and Horst (1989) indicates 
that self-induced target tissue deactivation of l,25-(OH)2D 
regulates 1,25-(OH) jD occupancy of VDR and ultimately the 
biopotency of 1,25-(OH) jD in target cells. However, Goff ^  
al. (1990) reported that under physiological conditions, 
increased plasma concentrations of 1,25-(OH) 2D do not result 
in up-regulation of tissue VDR concentration, and that dietary 
calcium restriction must induce some factor(s) that results in 
down regulation of VDRs in the kidney. 
In addition to induction of 24-OHase, there, are reports of 
1,25-(OH) 2D inhibition of lof-OHase in several tissues 
(Walters, 1992). It has been proposed that degradative enzymes 
such as vitamin D23 and D24 hydroxylases may be important 
regulators of cellular responsiveness to 1,25-(OH) jD because 
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of their ability to metabolize 1,25-(OH) 2D to inactive forms 
(Napoli and Horst, 1983; Reinhardt and Horst, 1989) . 
The therapeutic potential of vitamin D analogs 
The actions of the hormonal form of vitamin D extend 
beyond its role in mineral homeostasis (Brown ^  , 1994) . 
Receptor for this hormone has been identified in dozens of 
different target cells that respond to 1,25-(OH) 2D with a 
diverse range of biological actions including effects on cell 
differentiation and proliferation and the control of other 
hormonal systems (Walters, 1992). However, a major limitation 
of 1,25-(OH) 2D therapy is that the effective doses for many of 
these applications cause hypercalcemia (Brown ^  al., 1994). 
Hence, this has precluded the use of 1,25-(OH) 2D for treatment 
of malignancies and limited the use of vitamin D analog for 
psoriasis and HPT (Brown ^  , 1994) . 
However, analogs of vitamin D that are less calcemic, but 
retain the therapeutically useful properties of 1,25-(OH) jD, 
may provide a wider application of vitamin D therapy (Kubrusly 
et al. 1993) . Thus, many vitamin D analogs with therapeutic 
potential have been developed in recent years (Brown ^  , 
1990; Bikle, 1992). Analog with low calcemic activity 
represent the latest generation of clinically useful vitamin D 
compounds (Brown ^  , 1994) . 
Theoretically a vitamin D analog that is able to suppress 
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PTH without effects on plasma calcium and phosphate levels 
would be an ideal tool to control SHPT (Slatopolsky ^  , 
1984; Kubrusly ^  , 1993; Liou ^  ^. / 1994; Lee ^  al. . 
1994) . 
As reviewed by Brown ^  aJ.. (1994), l,25-(OH)2D3 
administration regulates PTH by several mechanisms. It can 
directly inhibit synthesis at the level of transcription and 
up-regulates the VDR in parathyroid cell to enhance its own 
activity. There is substantial evidence that treatment with 
1,25-(0H)2D3 in chronic renal disease may result in severe 
hypercalcemia and consequent suppression of PTH secretion 
(Slatopolsky et al., 1984). Furthermore, it can mediate the 
suppressive action of calcium by raising serum calcium and by 
increasing the sensitivity of the PTGs to calcium (Brown ^  
al., 1994). Thus, l,25-(OH)2D3 is widely used for the treatment 
of SHPT in patients with advanced renal failure in the United 
States (Brown et. al. , 1994) . 
Although a slight elevation in serum calcium by 1,25-
(OH) 2D3 can be beneficial in correcting the chronic 
hypocalcemia, the reduced capacity to eliminate excess calcium 
into the urine makes these patients very susceptible to 
hypercalcemia with l,25-(OH)2D3 therapy (Brown ^  al., 1994) . 
Furthermore, while there is increasing evidence that treatment 
of patients with less advanced renal failure may prevent the 
hyperplasia of the parathyroid glands there is a concern that 
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hypercalcemia may promote nephrocalcinosis and accelerate the 
loss of renal function which ultimately prevents the use of 
1,25-{0H)2D3 in early stages of renal disease (Brown ^  al.. 
1994). 
Vitamin D analog with lower calcemic activity that can 
suppress PTH may provide a safer alternative to 1,25-(011)203 
therapy in patients with moderate renal failure (Brown et al.. 
1994). However, another complication in these patients is 
hyperphosphatemia. High serum phosphate decreases serum 
ionized calcium and inhibit production of 1,25-(OH)2D3, the two 
important factors in controlling PTH. 
In addition, dietary phosphate restriction, independent of 
changes in calcium and l,25-(OH)2D3 can reduce PTH levels 
(Lopez-Hilker ^  ^. , 1990). Thus, the ideal vitamin D analog 
would also have low phosphatemic activities as well (Brown ^  
, 1994) . 
Several of the vitamin D analogs with low calcemic 
activity have been found to be nearly as effective as 1,25-
(0H)2D3 in suppressing PTH secretion by cultured parathyroid 
cells. These include 22-oxa-l,25-(OH) 2D3 (OCT) (Evans et al. 
1991; Kubruslv et al. . 1993), 1,25-(OH) 2-16-ene-23-yne-D3, 
1, 25-(OH) 2-24-dihomo-D3 and 1, 25-(OH) 2-24-trihomo-22-ene-D3 
(Brown ^  al., 1994) and 1,25,28-(OH) 3D2 (Goff ^  al., 1993). 
Brown ^  al. (1989) reported that OCT, despite its rapid 
clearance in vivo, could suppress PTH mRNA and low, submaximal 
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doses of OCT and l,25-(OH)2D3 produced comparable inhibition. 
Furthermore, OCT has also been shown to suppress serum PTH 
levels in uremic rats and dogs (Fukagawa ^  , 1991) . 
However, in every case the 1, 25-(OH) 2D3-treated animals had 
elevated calcium that could account for the lower PTH or PTH 
mRNA. Just as important as its low calcemic effects, OCT was 
found to be less phosphatemic than l,25-(OH)2D3 with lower 
activity on intestinal phosphate absorption and bone phosphate 
mobilization (Finch et 1993). Thus, OCT appears to offer 
major therapeutic advantages over l,25-(OH)2D3 in the treatment 
of SHPT in renal failure patients (Brown ^  , 1994) . 
Administration of vitamin D analogs 
Several reports have indicated that l,25-(OH)2D3 
administered intravenously rather than orally may result in a 
greater delivery of the vitamin D metabolite to peripheral 
target tissues other than the intestine and allow a greater 
expression of biological effects of l,25-(OH)2D3 in peripheral 
tissues (Slatopolsky ^  al. , 1984; Liou ^  , 1994; Lee ^  
al., 1994). 
However, recent studies have shown substantial degradation 
of 1,25-(0H)2D3 in the intestine. Hence, Napoli ^  (1983) 
and Slatopolsky ^  al. (1984) reasoned that while oral 
administration of l,25-(OH)2D3 may increase intestinal calcium 
absorption, the degradation of the vitamin D metabolite may 
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impair the delivery of l,25-(OH)2D3 to other peripheral target 
organs and thus limit the expression of direct biological 
effects. 
Furthermore, Liou ^  al. (1994) have compared the effect 
of oral versus intravenous calcitriol administration on SHPT 
in chronic hemodialysis patients. They concluded that both 
intravenous and oral treatments resulted in a significant 
decrement in blood levels of PTH. However, this PTH 
suppressive effect was more pronounced with intravenous 
therapy and could not be totally explained by either the 
higher dose or elevated serum calcium. 
A comparison of oral and intravenous alfacalcidiol in 
treatment of uremic HPT by Lee ^  (1994) showed that both 
routes were equally effective in suppressing HPT but they 
suggested that further controlled studies to find out the 
advantages of intravenous over oral vitamin D therapy. 
Calcitim and Phosphate Homeostasis 
Maintenance of calcium homeostasis 
The integrated actions of PTH on distal convoluted tubular 
calcium reabsorption, bone resorption, and 1,25-(0H)2D-
mediated intestinal calcium absorption are responsible for the 
fine regulation of the serum Ca^'' concentration (Broadus, 
1993) . 
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Distal convoluted tubular calcium reabsorption and 
osteoclastic bone resorption are the major control points in 
minute to minute serum calcium homeostasis; of these two 
processes, the effect of PTH on the distal convoluted tubule 
is quantitatively the most important. Therefore, together, 
these effects constitute a classical "short-loop" feedback 
system on the parathyroid chief cell. 
Adjustment in the rate of intestinal calcium absorption 
via the PTH-1,25-(OH)2D axis represents a classical "long-
loop" feedback system (Broadus, 1993) . 
During hypocalcemia, a series of physiological adjustments 
occur, leading to new steady state. A moderate increase in the 
secretion rate of PTH results in; 1) increased calcium 
reabsorption from the distal convoluted tubule; 2) increased 
mobilization of calcium and phosphorus from bone; and 3) 
increased synthesis of l,25-(OH)2D, which participates with 
PTH in bone resorption and increases the efficiency of calcium 
and phosphorus absorption in the intestine (Broadus, 1993). 
The increased circulating concentration of PTH resets the 
renal tubular phosphate threshold/glomerular filtration rate 
(TmPi/GFR) at a lower level, so that the increased amount of 
phosphorus mobilized from bone and absorbed from the intestine 
is cjuantitatively excreted into urine. Thus, in the new steady 
state, serum calcium has returned to normal, serum phosphorus 
is unchanged or slightly reduced and a state of mild secondary 
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HPT and efficient intestinal mineral absorption exists and the 
initial requirement for calcium mobilization from the skeleton 
is largely replaced by the enhanced absorption of calcium in 
the intestine (Broadus, 1993). 
The systemic mechanism for the prevention of hypercalcemia 
involves an inhibition of PTH and 1,25-(OH)jD synthesis, with 
a reduction in calcium mobilization from bone, absorption from 
the intestine and reclamation from the distal convoluted renal 
tubule. However, the bottleneck in the defense against 
hypercalcemia is the limited capacity of the kidney to excrete 
calcium. 
Limitations in the theoretical ability of the kidney to 
combat hypercalcemia include: 1) the fact that abnormalities 
in distal convoluted tubular reabsorption are actually in the 
genesis of hypercalcemia in a number of conditions (e.g., 
primary HPT); 2) the fact that a degree of renal impairment 
frequently accompanies many hypercalcemic conditions; and 3) 
the fact that an increased calcium concentration inhibit the 
ability of the renal tubule to conseirve water, which may lead 
to a vicious cycle of dehydration, prerenal azotemia and 
worsening hypercalcemia (Broadus, 1993). 
Maintenance of phosphate homeostasis 
The kidney plays the dominant role in systemic phosphate 
homeostasis and maintains the serum phosphorus concentration 
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at a value close to the TmPi/GFR. 
However, because of the normal efficiency and lack of fine 
regulation of phosphorus absorption in the intestine, only in 
unusual circumstances {e.g., prolonged use of phosphate-
binding antiacids) is the systemic supply of phosphorus a 
limiting factor in phosphate homeostasis. Thus, most disorders 
associated with chronic hypophosphatemia and/or phosphorus 
depletion in humans result from either intrinsic (e.g., 
familial hypophosphatemia rickets) or extrinsic {e.g., primary 
HPT) alterations in TmPi/GFR. Similarly, most conditions of 
chronic hyperphosphatemia result from intrinsic {e.g., renal 
impairment or HPT) abnormalities in the renal threshold for 
phosphorus. However, acute hypophosphatemia most commonly 
results from the flux of extracellular phosphate ions into 
soft tissues. 
The sequence of events initiated in the face of a 
hypophosphatemic challenge include: 1) stimulation of 1,25-
{0H)2D synthesis in the kidney; 2) enhanced mobilization of 
phosphorus and calcium from bone; and 3) hypophosphatemia 
induced increase in TmPi/GFR {the exact mechanism is unknown) . 
The increased circulating concentration of 1,25-{OH) 2D 
leads to increases in phosphorus and calcium absorption in the 
intestine and provides an additional stimulus to phosphorus 
and calcium from bone. The increased flow of calcium from bone 
and the intestine results in an inhibition of PTH secretion 
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which diverts the systemic flow of calcium into the urine and 
further increases TmPi/GFR. Thus, net result of this sequence 
of adjustment is a return of the serum phosphorus 
concentration to normal without change in the serum calcium 
concentration (Broadus, 1993). 
The defense against hyperphosphatemia consists largely of 
a reversal of the sequence of adjustments described above. The 
principal humoral factor that combats hyperphosphatemia is 
PTH. An acute rise in the serum phosphorus concentration 
produces a transient fall in the concentration of serum 
ionized calcium and a stimulation of PTH secretion, which 
reduces TmPi/GFR and leads to a readjustment in serum 
phosphorus and calcium concentrations. Hence, a prolonged rise 
in the serum phosphorus concentration results in: 1) an 
intrinsic downward adjustment in TmPi/GFR that is independent 
of PTH; and 2) a persistent increase in PTH secretion that can 
ultimately lead to chief cell hyperplasia. If 
hyperphosphatemia is prolonged and severe (e.g., as occurs in 
chronic renal insufficiency), the degree of SHPT is sufficient 
to lead to the typical finding of parathyroid bone disease. 
Hyperparathyroidism 
All HPT disorders are characterized by elevated 
circulating levels of PTH that arise from augmented PTH 
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production/secretion per cell and/or from an expanded number 
of functioning PTH producing cells (Galbraith and Quarles, 
1993). 
However, the variable underlying pathophysiologicaly of 
increased PTH secretion permits subclassification of HPT into 
primary and secondary disorders. 
Primary HPT is characterized functionally by an abnormal 
synthesis and secretion of PTH in excess of calcium 
homeostatic needs and morphologically by adenomatous 
transformation or diffuse hyperplasia of PTH secreting cells. 
Furthermore, it is pathophysiologically associated to the loss 
of normal feedback control of PTH secretion by extracellular 
calcium (Bilezikian, 1993). 
SHPT, in contrast, is an an acquired disorder representing 
a normal physiological response to perturbations in calcium 
metabolism (Galbraith and Quarles, 1993). However, tertiary 
HPT is a term used to describe patients with sustained SHPT 
who develop elevated levels of serum calcium, whereas the term 
refractory SHPT defines a second subset of patients with 
severe SHPT without hypercalcemia that displays non-
suppressible PTH secretion after correcting the inciting 
metabolic abnormalities. Thus, in both tertiary and refractory 
HPT, the PTG has reached a hyperfunctioning state that no 
longer responds appropriately to physiological regulation 
(Galbraith and Quarles, 1993) . 
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Secondary Hyperparathyroidism and Renal 
Insufficiency 
SHPT is a universal complication of chronic renal 
insufficiency frequently found in patients with end-stage 
renal disease and is an important cause of morbidity in 
patients on maintenance dialysis (Massry ^  , 1980; 
Slatopolsky ^  al. , 1984; Massry, 1986; Lee ^  , 1994; Liou 
et al., 1994) . 
PTH acts upon the proximal convoluted cell to increase the 
production of l,25-(OH)2D3 (Garabedian et , 1972; 
Slatopolsky et , 1984; Johnson and Kumar, 1994), which in 
turn increases intestinal calcium absorption. Therefore, it 
seems possible that a negative feedback system could operate 
to regulate PTH secretion (Slatopolsky ^  1984) . In severe 
renal insufficiency the lack of l,25-(OH)2D3 could thus be a 
factor in maintaining the hypersecretion of PTH (Slatopolsky 
et al., 1984; Liou ^  al., 1994; Johnson and Kumar, 1994) . 
Thus, the principal cause of HPT is loss of activity of the 
renal la-OHase enzyme and impaired production of l,25-(OH)2D3 
from its precursor 25-OHD (Kubrusly ^  aJL. , 1993; Lee ^  al. . 
1994) . 
Therefore, chief cell hyperplasia of the PTG and high 
levels of PTH are among the earliest alterations in mineral 
metabolism obseirved in patients with chronic renal 
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insufficiency (Slatopolsky ^  , 1992) . 
An important mechanism for the increased PTH levels in 
chronic renal failure may be a shift in the set-point (at 
which 50% maximum PTH secretion is achieved) for calcium 
regulated PTH secretion in addition to an increase in the mass 
of parathyroid tissue. It has been indicated that the set-
point for calcium in normal parathyroid cells is approximately 
1.0 mM calcium, whereas in patients with SHPT, the set-point 
is increased to 1.26 mM calcium (Brown ^  al., 1978 and 1982) . 
In addition to the effect of l,25-(OH)2D3 and serum calcium on 
the regulation of PTH secretion, phosphorus retention in 
chronic renal failure has shown to affect the degree of SHPT 
(Slatopolsky ^  al., 1992). 
Reports by Portale et (1984) ; Llach and Massry (1985) 
and Portale et (1986) indicated that restriction of 
dietary phosphorus increases the production of 1,25-(OH) 2D3, 
thus, decreasing the level of immunoreactive PTH (iPTH). 
However, this mechanism may not be operative in advanced renal 
insufficiency because the decrease in renal mass may severely 
limit the production of 1,25-(OH) 2D3. 
Studies in dogs by Lopez-Hilker ^  (1990) suggested 
that reduction in dietary phosphate in advanced renal 
insufficiency improves SHPT by a mechanism which is 
independent of the level of l,25-(OH)2D3 or serum ionized 
calcium. Several reports have provided evidence for reduced 
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plasma concentration of l,25-(OH)2D3 in mild or moderate 
chronic renal failure. This low plasma levels could be 
interpreted merely as the consequence of the reduced mass of 
renal tubular cells capable of producing 1,25-(OH)2D3. 
However, experimental and clinical data cast serious doubt 
on this simple explanation. Rather, a reduced circulating 
level of 1,25-(0H)2D3 in early chronic renal failure might 
represent an adaptive response to a primary disturbance in 
Phosphate homeostasis, the exact nature of which has not yet 
been appreciated (Bonjour et al., 1992) . 
For many years, PTH has been considered to be the main 
regulator of plasma Phosphate homeostasis, principally because 
of its action on renal Phosphate reabsorption. However, PTH 
cannot function as the major regulator of Phosphate 
homeostasis, since the secretion of PTH is primarily 
controlled tightly by the Phosphate status itself (Bonjour and 
Fleisch, 1980). 
Reports by Bonjour ^  (1982a) indicated that there are 
two very specific PTH-independent mechanisms that rapidly 
respond to variations in Phosphate status in such a way that 
they tend to maintain Phosphate homeostasis despite 
fluctuations either in the supply of dietary Phosphate or in 
its utilization for bone mineralization or cellular 
metabolism. Bonjour ^  (1992) indicated that these two 
mechanisms are the production of 1,25-(0H)2D3 and the capacity 
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of renal tubule to respond to changes in Phosphate status with 
changes in Phosphate transport. Further, Bonjour ^  al. 
(1982b) and Insogna ^  al. (1983) indicated that both the 
renal production of l,25-(OH)2D3 and the capacity of tubular 
reabsorption are rapidly stimulated in response to a 
restriction in supply of Phosphate. These two systems are 
fully effective even in the absence of PTH. However, Bonjour 
et al. (1982a and b) reported that increased production of 
1,25-(OH) 2D3, in response to Phosphate deprivation, does not 
stimulate tubular Phosphate transport under vitamin D-replete 
conditions. Similarly, there is no direct evidence indicating 
that the stimulation of tubular Phosphate transport during 
restriction is responsible for enhanced production of 1,25-
(OH)2D3 (Bonjour ^  , 1992) , 
To understand Phosphate homeostasis in early chronic renal 
failure, it is also important to bear in mind that the 
concentration of extracellular Phosphate can be set at 
different levels according to needs of the organism, with 
Phosphate levels being mainly determined by the tubular 
reabsojrption of Phosphate (Bonjour ^  , 1992). Thus, when 
Phosphate needs are diminished, as, for instance, when there 
is a reduction in body growth and/or bone mineralization, 
T„Pi/GFR, and also l,25-(OH)2D3 production will be set at a 
lower level. The reduced T„Pi/GFR and l,25-(OH)2D3 would lead to 
a fall in plasma Phosphate concentration and could be 
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considered, therefore, as physiologically appropriate for 
Phosphate homeostasis (Bonjour ^  al., 1992). This notion 
implies that the level of extracellular Phosphate itself is 
not the ultimate variable that the homeostatic system attempts 
to maintain constant, but rather the balance between the 
supply and utilization of Phosphate. This putative pool is 
most likely an intracellular one, but it is neither 
necessarily nor exclusively within the renal tubular cells 
endowed with the l,25-(OH)2D3 producing machinery (Bonjour et 
al., 1992). According to this concept, the two controlling 
elements of Phosphate homeostasis, namely, the adaptive 
tubular Phosphate transport and the 1,25-(0H)2D3 producing 
system, would act in concert to maintain a constant critical 
intracellular Phosphate pool. Reports indicated further that 
these two renal controlling mechanisms would be 
physiologically linked to this "internally controlled pool" of 
Phosphate by a single specific signal which probably 
corresponds to a still unknown hormonal factor (Bonjour ^  
, 1992) . 
Along the notion of Phosphate homeostasis, it is important 
to consider the consequence of reduced renal mass on the 
plasma levels of l,25-(OH)2D3 before examining the situation in 
early chronic renal failure. However, in experimental studies, 
it has been shown that the plasma levels of l,25-(OH)2D3 do not 
fall significantly within the first few hours of days 
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following unilateral nephrectomy in the rat (Taylor ^  , 
1983). 
Similarly, in healthy human kidney donors, the remaining 
kidney appears to compensate very rapidly to a 50% reduction 
in the renal mass (Lucas ^  al-/ 1986). Furthermore, studies 
in unilaterally nephrectomized rats have shown that the 
remaining kidney has a marked capacity to increase its 
production of l,25-(OH)2D3 in response to a reduction in the 
dietary intake of calcium (Taylor ^  al., 1983). 
It is interesting to compare the pathophysiologic sequence 
with that proposed many years ago by Slatopolsky ^  al. (1966 
and 1968) from which the very attractive "trade-off" 
hypothesis was developed to explain the reactive HPT observed 
in chronic renal failure (Bricker, 1972) . Although, these two 
sequences differ in several aspects, they have in common one 
very important element: both theories consider a disturbance 
in Phosphate homeostasis, more precisely a Phosphate overload, 
as the primary alteration occurring in early chronic renal 
failure (Bonjour ^  , 1992) . 
However, according to the earlier theory (Slatopolsky ^  
al. 1966 and 1968; Bricker, 1972), Phosphate overload would be 
mainly in the extracellular compartment. The loss of nephrons 
and the consequent fall in GFR would result in transient 
increase in plasma Phosphate that would be rapidly corrected 
by an increase in PTE secretion. This in turn, would lead to a 
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reduction in T„Pi/GFR. Thus, the first trade-off operation for 
maintaining Phosphate homeostasis would comprise the 
hypersecretion of PTH and the reduced renal mass and possibly 
the hyperphosphatemia would account for the insufficient 
production of 1,25-(OH) 2D3. 
However, despite its attractiveness, there are several 
difficulties with this pathophysiologic concept: 1) plasma 
Phosphate does not increase in early or moderate chronic renal 
failure, but rather tends to be set at levels lower than 
normal (Wilson ^  al. , 1985; Portale ^  1984); 2) PTH is 
not essential for the reduction in T„Pi/GFR observed in the 
course of chronic renal failure (Caverzasio et al,. , 1982) ; and 
3) l,25-(OH)2D3 production cannot be considered as insufficient 
or defective in early chronic renal failure. Indeed, it is not 
maximal at normal intake of Phosphate since it can be further 
stimulated by a low diet (Portale ^  , 1984) . 
According to the new theory developed, the overload of 
Phosphate would affect the intracellular rather than the 
extracellular compartment. The first consequence of this 
overload would be a compensatory reduction in l,25-(OH)2D3 
production and T„Pi/GFR. Thus, instead of PTH, the first 
element of the homeostatic system trade-off would be 1,25-
(0H)2D3, its reduced production counteracting the Phosphate 
overload (Bonjour ^  , 1992) . HPT would in this view be 
only a consequence of the low production of l,25-(OH)2D3 that 
48 
could lead to a lower plasma calcium, changes in the set-point 
of the PTH secretory process, and a reduction in the calcemic 
response to PTH (Llach ^  , 1975; Massry, 1985a; Lopez-
Hilker et , 1986; Delmez ^  , 1989; Rodriguez ^  al. . 
1991a and b). Feinfeld and Sherwood (1988) have also 
independently suggested that the decrease in l,25-(OH)2D3 
observed in early chronic renal failure was a consequence of a 
primary disturbance in Phosphate homeostasis. 
In summary, PTH is a polypeptide hormone of 84 amino acids 
which utilizes the first 1-34 amino acids for its biological 
actions. Its signal transduction pathways are either cAMP or 
IP3. PTH maintains the extracellular calcium via bone 
resorption and by stimulating the activities of la-OHase in 
the proximal convoluted tubule of the kidney. It has been 
suggested that the major regulators of PTH synthesis and 
secretion are Ca.^'" and l,25-(OH)2D. 
The vitamin D precursors are either obtained from the diet 
or synthesized in the skin. These are processed in the 
intestine, metabolized in the liver and finally the 
biologically active form, l,25-(OH)2D, is synthesized in the 
kidney. On top of many biological functions, 1,25-(OH) jD is 
primarily involved in the absorption of calcium and phosphate 
by stimulating the synthesis of CaBP and Ca-ATPase proteins in 
the intestinal cells. 
The homeostasis of calcium and phosphate are maintained 
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primarily by the concerted actions of PTH and 1,25-(OH) jD. 
However, during renal failure, the production of 1,25-(OH)jD 
is lowered due to reduced mass of renal tissue. On the other 
hand, high phosphorus diet leads to hyperphosphatemia and 
eventually inhibit la-OHase and raise plasma PTH. Low 1,25-
(OHjjDa and hyperphosphatemia are among the features of SHPT. 
Several reports indicated that phosphorus restriction and 
the use of some of the vitamin D analogs as a treatment might 
be the therapeutic alternative to lower excessive PTH levels 
and consequently restoring calcium and phosphate homeostases. 
Therefore, the use of some of the vitamin D analogs with 
therapeutic potential in combating SHPT would be a choice 
provided that the effective doses of each one of these analogs 
are worked out. However, attention must be given to the level 
of dietary phosphorus whenever such therapies would be taken. 
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MATERIALS AND METHODS 
Animals 
Protocols for the use of animals were approved by the 
Institutional Animal Care and Use Committee of the USDA, 
Agricultural Research Service, National Animal Disease Center 
(NADC). One hundred twelve male Harlan Sprague-Dawley rats 
that were 60-day-old and on an average of 400 ± 50 gm body 
weight were used in this study. 
All rats were housed individually under fluorescent 
lighting on a 12 hour on, 12 hour off lighting cycle during 
the entire study period (Lieuallen ^  al., 1990). 
Diets and Feeding 
Upon arrival all rats were fed a standard laboratory rat 
chow (Diet C in this study) containing 1.01% calcium, 0.74% 
phosphorus, and 3.3 lU/gm vitamin D. All rats were fed this 
diet for two weeks of adaptation. 
At the end of the two weeks period, that is at the 
beginning of experimentation, all rats were fed the 
experimental diets. 
Two synthetic diets, namely Diet A and B containing low 
phosphorus (LP) and high phosphorus (HP) levels, respectively. 
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were purchased from Harlan Teklad, Madison, Wisconsin. The Ca, 
P, and vitamin D contents of all the diets (on an as fed 
basis) used in this study were as follows: 
Diet Ca P Na K vitamin D 
( % )  ( % )  ( % )  ( % )  (lU/gm) 
A 0.48 0.40 0.20 0.90 5.0 
B 0.35 3.22 1.32 2.00 5.0 
C 1.00 0,74 0.28 
CO o
 3.3 
In order to avoid overeating of the diets particularly by 
the sham groups, a fixed amount of the diets was weighed and 
offered every day until the end of experiment. Following 
unilateral nephrectomy, the rats were maintained on standard 
laboratory rat chow for 5 days for recovery. The feeding 
period was 3 0 days and water was offered ad libitum. 
Body Weight Measurements 
Body weight measurements (gm) were made for each rat at 
the beginning and at the end of the experiment. Body weight 
changes {%) were calculated from the differences between the 
beginning and end body weights expressed as a pecentage. 
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Design of the Study 
At the end of the two weeks period of adaptation, all rats 
were randomly picked and divided into 7 groups. 
Group Treatment Diet Vit. D Analog 
SLP Sham Low P 
SHP Sham High P 
NLP Nephrectomy Low P 
NHP Nephrectomy High P 
NHP-A Nephrectomy High P 1,25-(0H)2D3 
NHP-B Nephrectomy High P 1,25-(0H)2D2 
NHP-C Nephrectomy High P 1,25,28- (0H)3D2 
Nephrectomy 
The unilateral nephrectomy in this study was done as 
follows: Each rat was anesthetized with intraperitoneal 
injections of 60 mg/kg Ketamine and shaved ventro-dorsally and 
the entire left kidney was removed via a left paracostal 
approach (Lieuallen ^  , 1990) . 
An incision was made into the abdominal cavity, down the 
side of the rat near to the last rib. The kidney was freed of 
connective tissue and was pulled out gently, preferably by 
grasping the peripheral fat. The adrenal gland which was 
attached loosely to the anterior pole of the kidney by 
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connective tissue and fat was gently freed by tearing the 
attachments. Then, a single ligature was placed around the 
renal blood vessels and the ureters as far from the kidney as 
possible, towards the midline, but without damaging or 
occluding any collateral blood vessels that may be 
encountered. Then, the ligature was tied securely with a 
double reef-knot and the blood vessels were transected next to 
the kidney which was removed. Finally, the incision was closed 
(Waynforth, 1980). 
Oral Administration of Vitamin D Analogs 
1,25-(0H)2D3, 1,25-(0H)2D2, and 1, 25, 28-(OH) 3D2 (Figure 1) 
were provided by Dr J.P. Goff and Dr R.L. Horst. The 
concentration of these analogs was determined by UV absorption 
with molar extinction coefficient for D2 analogs being 19600 
and for D3 analogs being 18300. The solutions were mixed with 
corn oil as carrier after each dose was adjusted to 200 /zl. 
Then they were evaporated to dryness by Nitrogen gas to remove 
diethylether. The volume for each week administration was put 
in falcon blue tubes and stored at - 20°C. After each use, the 
remainder of the mixture was always maintained at - 20°C. 
The vitamin D analogs were delivered to each rat by using 
1 ml syringe orally every day between 9.00 to 10.00 am until 
the end of the experiment. The feeding of diets and vitamin D 
i;I5^ oh)3Di 
l,25(OH),D, 
Structure of vitamin D analogs used in this study 
(Adapted from Goff et. , 1993, and Norman, 1979) , 
55 
analogs administration began the same day. The dose of each 
analog is as follows: 
Vitamin D analog Corn oil (/ul) Dose/day 
1,25-(0H)2D3 200 18 ng 
1,25-(0H)2D2 200 18 ng 
1,25,28-(OH) 3D2 200 2 /xg 
Sample Collection and Plasma Analyses 
After 30 days of feeding and oral treatment of vitamin D 
analog, all rats were weighed and rendered unconscious with 
CO2-O2 (50%:50% vol/vol) and decapitated. Blood sample was 
collected into tubes containing heparin and then it was 
centrifuged for 5 minutes at 2300 rpm. Plasma was aspirated 
and stored at 4°C until analysis. 
Samples were analyzed for calcium, inorganic phosphorus, 
1,25-(OH)2D3, PTH, and creatinine. The plasma calcium 
concentration was determined by atomic absorption 
spectrophotometry (Perkin-Elmer Corp. 1965). The plasma 
phosphorus concentration was determined by a colorimetric 
assay (Parekh and Jung, 1970). The plasma l,25-(OH)2D3 
concentration was determined by the method of Reinhardt et al. 
(1984). Intact PTH was determined by rat PTH immunoassay kit 
from Nichols Institute Diagnostics (1995) according to the 
methods of Nussbaum ^  al. (1987) and Reiss ^  (1968) , and 
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the plasma creatinine was determined by creatinine kit from 
Sigma Diagnostics (1992) following the method of Chasson ^  
al. (1961) . 
One-way analysis of variance (2^0VA) was employed to test 
the hypotheses that: 1) means from sham operated or 
unilaterally nephrectomized rats were the same; 2) means from 
rats fed low or high phosphorus diets were not different, and; 
3) means from rats treated or not treated with vitamin D 
analogs were the same. Where the ANOVA were different Tukey-
Kramer Multiple Comparisons Test was used to test for 
differences among the means according to Snedecor and Cochran 
(1980). 
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RESULTS 
The mean body weight change (%) of eight groups of rats is 
presented in Table 1. The loss of body weight of SHP was 
higher (P<0.001) than the SLP rats. SHP rats lost 9.50% of the 
initial body weight. But SLP rats gained 14.95% of the initial 
body weight. The mean body weight loss of NHP was higher 
{P<0.001) than the NLP rats. NHP rats lost 24.72% of thier 
initial body weight whereas NLP rats gained 17.12% of their 
initial body weight. The loss of body weight of the NHP-A and 
NHP-C groups was not significantly {P>0.05) different from the 
NHP rats. But still their body weight losses were lower than 
the control rats. The body weight loss of NHP-B was 
significantly (P<0.01) less than the control rats. NHP-A, NHP-
B and NHP-C rats lost {%) 20.32 ± 2.03, 13.87 ± 2.70 and 20.06 
± 2.41, respectively, of their initial body weights. It is 
clear that rats on high phosphorus diets lost more body weight 
as compared than the control rats. But the application of 
vitamin D analogs were found to be helpful in reducing the 
losses in vitamin D treated rats. Particularly, the 
application of 1,25-(0H)2D2 was found to be superior in 
reducing the body weight losses in NHP-B rats as compared to 
the other two vitamin D analogs. 
Inorder to prove that feeding a high phosphorus diet to 
patients with renal failure (reduced renal tissue mass) 
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increases plasma phosphate, four groups of rats SLP, SHP, NLP 
and NHP were fed low or high phosphorus diets for 30 days 
(Figure 2). The mean plasma phosphate (mg/dl) of SHP rats was 
significantly (P<0.001) higher than SLP rats. Similarly, the 
mean plasma phosphate of NHP rats was significantly {P<0.001) 
higher than the NLP rats. 
Three groups of rats NHP-A, NHP-B and NHP-C were orally 
administered three different kinds of vitamin D analogs for 3 0 
days. The analog groups were compared to the NHP group. The 
result (Figure 3) indicates that NHP-B and NHP-C rats treated 
with 1,25-(0H)2D2 and 1,25,28-(OH) 3D2, respectively, had 
significantly (P<0.001) reduced plasma phosphate as compared 
to the control rats. Although plasma phosphate of NHP-A 
treated rats was not significantly different from the NHP 
rats, the treatment of l,25-(OH)2D3 lowered plasma phosphate by 
5% compared to the NHP rats. 
The mean plasma calcium concentration (mg/dl) of SLP, SHP, 
NLP and NHP were 8.07 + 0.08, 6.70 ± 0.09, 9.14 ± 0.09 and 
7.19 ± 0.10, respectively (Figure 4). The mean plasma calcium 
of SHP was significantly (P<0.001) lower than SLP rats. 
Similarly, the mean plasma calcium of NHP rats was 
significantly (P<0.001) lower than NLP rats. 
The mean plasma calcium concentration (mg/dl) of NHP, NHP-
A, NHP-B and NHP-C were 7.19 ± 0.10, 8.29 ± 0.15, 8.86 ± 0.16 
and 8.50 ± 0.15, respectively (Figure 5). The mean plasma 
59 
calcium concentration of NHP-A, NHP-B and NHP-C were 
significantly (P<0.001) higher than the NHP rats. Therefore, 
the applications of vitamin D analogs proved to improve the 
conditions of SHPT by increasing the plasma calcium. 
The mean plasma 1,25-(0H)2D3 concentration (pg/ml) of SLP, 
SHP, NLP and NHP were 75.76 ± 3.70, 50.3 0 ± 6.33/ 98.17 ± 4.25 
and 22.94 ± 2.51, respectively (Figure 6). The mean plasma 
1,25-(0H)2D3 of SHP was significantly (P<0.G1) lower than the 
SLP rats. Similarly, the mean plasma l,25-(OH)2D3 of NHP was 
significantly (P<0.001) lower than the NLP rats. 
The mean plasma l,25-(OH)2D3 concentration (pg/ml) of NHP, 
NHP-A, NHP-B and NHP-C were 22.94 ± 2.51, 36.76 ± 2.72, 76.37 
± 5.59 and 30.52 ± 3.53, respectively (Figure 7). The mean 
plasma l,25-(OH)2D3 of NHP-A and NHP-C were not significantly 
different from NHP rats. However, the mean plasma l,25-(OH)2D3 
of NHP-B was significantly (P<0.001) higher than the NHP rats. 
Thus, it seems likely that high phosphorus diet has inhibited 
the lof-OHase enzyme and consequently lowered plasma 1,25-
(OH) 2D3 production. 
The mean plasma PTH concentration (pg/ml) of SLP, SHP, NLP 
and NHP were 41.14 ± 2.15, 131.20 ± 3.53, 34.07 ± 1.16 and 
267.16 + 5.31, respectively (Figure 8). The mean plasma PTH 
concentration of SHP rats was significantly {P<0.001) higher 
than the SLP rats. Similarly, the mean plasma PTH of NHP was 
significantly (P<0.001) higher than the NLP rats. 
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The mean plasma PTH concentration (pg/ml) of NHP, NHP-A, 
NHP-B and NHP-C were 267.16 ± 5.31, 206.79 + 8.95, 207.16 ± 
8.17 and 324.72 ± 12.84, respectively (Figure 9). The mean 
plasma PTH of NHP-A and NHP-B were significantly (P<0.001) 
lower than the NHP rats. But the mean plasma PTH of NHP-C was 
significantly {P<0.001) higher than the control rats. 
The mean plasma creatinine concentration (mg/dl) of SLP, 
SHP, NLP and NHP were 1.40 ± 0.03, 2.21 ± 0.05, 4.47 ± 0.02 
and 4.50 ± 0.08, respectively (Figure 10). The mean plasma 
creatinine of SHP was significantly (P<0.001) higher than the 
SLP rats. However, there was no significant difference between 
NHP and NLP rats. 
The mean plasma creatinine concentration (mg/dl) of NHP, 
NHP-A, NHP-B and NHP-C were 4.50 ± 0.08, 6.05 ± 0.03, 7.26 ± 
0.21 and 6.77 + 0.06, respectively (Figure 11). The mean 
plasma creatinine of NHP-A, NHP-B and NHP-C were significantly 
(P<0.001) higher than the NHP rats. 
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Table 1. Change in body weight {%) of sham, nephrectomized and 
nephrectomized and vitamin D analogs treated rats fed 
either high or low phosphorus diets for 30 days. 
Treatments Body weight change (%)* P value 
SLP + 14.95 ± 1.12 
SHP - 9.50 + 3 .96 PcO.OOl 
NLP + 17.12 + 1. 08 
NHP - 24.72 ± 1.80 P<0.001 
NHP-A - 20.32 + 2.03 ns 
NHP-B - 13.87 + 2.70 P<0.01 
NHP-C - 20.06 + 2 .41 ns 
+ = gain in body weight. 
- = loss in body weight. 
* = mean ± SEM (standard error of mean). 
ns = not significant. 
Figure 2. Mean plasma phosphate (mg/dl) of sham and 
nephrectomized rats fed either low or high 
phosphorus diets for a period of 30 days, 
a = significantly different from SLP P<0.001. 
b = significantly different from NLP P<0.001. 
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SLP SHP NLP NHP 
TREATMENTS 
Figure 3. Mean plasma phosphate (mg/dl) of nephrectomized 
rats fed high phosphorus diets and treated with 
vitamin D analogs for a period of 30 days, 
a = significantly different from NHP P<0.001. 
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201 
NHP NHP-A NHP-B NHP-C 
TREATMENTS 
Figure 4. Mean plasma calcium (mg/dl) of sham and 
nephrectomized rats fed either low or high 
phosphorus diets for a period of 30 days, 
a = significantly different from SLP P<0.001. 
b = significantly different from NLP P<0.001. 
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10 1 
SLP SHP NLP NHP 
TREATMENTS 
Figure 5. Mean plasma calcium (mg/dl) of nephrectomized rats 
fedhigh phosphorus diets and treated with vitamin 
D analogs for a period of 30 days, 
a = significantly different from NHP P<0.001. 
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NHP NHP-A NHP-B NHP-C 
TREATMENTS 
Figure 6. Mean plasma 1,25-(0H)2D3 (pg/ml) of sham and 
nephrectomized rats fed either low or high 
phosphorus diets for a period of 30 days, 
a = significantly different from SLP P<0.001. 
b = significantly different from NLP P<0.001. 
71 
SLP SHP NLP NHP 
TREATMENTS 
Figure 7. Mean plasma l,25-(OH)2D3 (pg/ml) of nephrectomized 
rats fed high phosphorus diets and treated with 
vitamin D analogs for a period of 3 0 days, 
a = significantly different from NHP P<0.001. 
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NHP NHP-A NHP-B NHP-C 
TREATMENTS 
Figure 8. Mean plasma PTH (pg/ml) of sham and nephrectomized 
rats fed either low or high phosphorus diets for a 
period of 3 0 days. 
a = significantly different from SLP P<0.001. 
b = significantly different from NLP P<0.001. 
300-
200-
Figure 9. Mean plasma PTH (pg/ml) of nephrectomized rats fed 
either low or high phosphorus diets for a period 
of 30 days. 
a = significantly different from NHP P<0.001. 
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Figure 10. Mean plasma creatinine (mg/dl) of sham and 
nephrectomized rats fed either low or high 
phosphorus diets for a period of 30 days, 
a = significantly different from SLP P<0.001. 
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Figure 11. Mean plasma creatinine (mg/dl) of nephrectomized 
rats fed high phosphorus diets for a period of 30 
days. 
a = significantly different from NHP P<0.001. 
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DISCUSSION 
Results reported in this study are in agreement with many 
results reported earlier. Body weight losses were found to be 
higher in nephrectomized rats fed high phosphorus diets. 
Probably the main reasons could be loss of appetite compounded 
and dehydration due to loss of water to overcome the kidney 
overload with phosphates. The build up of phosphate further 
destroys the tubules and reduces T„Pi/GFR and most importantly 
interferes with hormone secretion such as erythropoietin which 
is ultimately required for RBC synthesis. Furthermore, the 
functional losses of the kidney functions (filtration, 
secretion and reabsorption) also contributes to the increased 
water. The lowered reabsorption of the Na'' ion from the kidney 
tubules cause for decreased blood volume and decreased 
systemic pressure. The high value of phosphate in the diets 
reduces the palatability of the diets which ultimately leads 
to lowered feed intake. From personal observations, most of 
the rats under the study did not like the high phosphorus diet 
and they preferred to drink more water. However, the loss of 
body weights in other studies were not observed. Lieuallen ^  
al. (1990) did not see significant differences in weights 
between the different nephrectomized rats fed different 
calcium and phosphorus combinations in the diets. 
Feeding high dietary phosphorus shown to increase the 
83 
plasma phosphate in this study. Sham operated and 
nephrectomized rats fed on high dietary phosphorus had high 
plasma phosphate as compared to rats fed on low phosphorus 
diets. Thus, feeding high dietary phosphorus to patients with 
renal failure would lead to hyperphosphatemia and ultimately 
worsen the situation of renal insufficiency. Support for the 
major role of phosphorus retention has been provided by 
several investigators who have shown that decreasing the 
amount of phosphorus in the diet in proportion to the fall in 
GFR prevents or ameliorates SHPT (Bricker ^  al., 1969; 
Slatopolsky ^  al., 1972; Lopez-Hilker ^  , 1990). However, 
in this study treatments with vitamin D analogs were shown to 
reduce plasma phosphate and improve the situations. The 
reductions of plasma phosphate by the use of l,25-(OH)2D2 and 
1, 25,28-(OH) 3D2 were very significant. Although not 
statistically significant, 1,25-{0H)2D3 also reduced plasma 
phosphate. Thus, overall it is possible to say that treatments 
by vitamin D analogs lowered substantially phosphate levels 
and they were beneficial for the treatments of SHPT. 
Plasma calcium in this study was found to be depressed by 
high levels of plasma phosphate. In both sham and 
nephrectomized rats, high dietary phosphorus showed to lower 
plasma calcium. This could be due to the fact that 
hyperphosphatemia results in hypocalcemia by several possible 
mechanisms including inhibition of the activity of the renal 
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enzyme of la-OHase which is already limited by the decrease in 
renal mass (Tanaka and DeLuca, 1973; Lopez-Hilker ^  al.. 
1990). The application of vitamin D analogs was found to be 
successful because plasma calcium was raised from lower levels 
to nearly normal levels. Thus, 1,25-(OH) 2D3, 1,25-(0H)2D2 and 
1,25,28-(OH) 3D2 were found to improve plasma calcium levels in 
NHP-A, NHP-B and NHP-C rats, respectively. 
The production of l,25-(OH)2D3 in sham operated rats fed 
high dietary phosphorus was found to be lower than the SLP 
group which fed low dietary phosphorus. Similarly, in 
nephrectomized rats, those fed high dietary phosphorus were 
found to be lower in their l,25-(OH)2D3 production. Therefore, 
1,25-(0H)2D3 was found to be limited by two major factors in 
this study. These were hyperphosphatemia which inhibited lot-
OHase activities and the reduced renal cell mass which also 
limited the capacity of the proximal renal tubule to synthesis 
1, 25-(OH) 2D3. Portale ^  (1986) and Lopez-Hilker ^  al. 
(1990) reported that when dietary phosphorus was restricted 
and then supplemented, an increase and then a decrease in 
plasma 1,25-{0H)2D3 was found. Furthermore, they reported that 
this phenomenon was associated with an increase and decrease 
in the production rate of 1,25-(OH)2D3, respectively. Gray ^  
al. (1977) also demonstrated in healthy women an increase in 
1,25-(0H)2D3 levels in response to dietary phosphorus 
restriction. In patients with severe and moderate renal 
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insufficiency, the occurrence of severe and moderate renal 
reductions in plasma concentrations of l,25-(OH)2D3 presumably 
reflects a reduction in the renal synthesis of 1,25-(0H)2D3 
(Portale et , 1984) . The present study supported that in 
rats with renal insufficiency, the application of 1,25-(OH)2D3, 
1,25-(0H)2D2 and 1,25,28-(OH) 3D2 had improved the plasma levels 
of l,25-(OH)2D3 greatly. Improvements were found to be 60, 232 
and 33% more than the control for NHP-A, NHP-B and NHP-C, 
respectively. 
The stimulatory effect of hyperphosphatemia to HPT was 
observed in this study. Sham rats fed high dietary phosphorus 
were tripled their PTH production compared to the control rats 
fed low phosphorus diets. Similarly, nephrectomized rats fed 
high dietary phosphorus had increased their PTH production 
more than seven-fold as compared to the control rats. 
The therapeutic potentials of some of the vitamin D 
analogs were confirmed in this study by the fact that 1,25-
(OH) 2D3 and l,25-(OH)2D2 reduced the PTH production by 23 and 
22%, respectively. However, 1,25,28-(OH) 3D2 was not likely to 
improve the situations. 
The actions of phosphorus restriction or supplementation 
on PTH and l,25-(OH)2D3 have been documented in several 
reports. Thus, phosphorus retention has long been considered 
to be important to the pathogenesis of the SHPT of chronic 
renal failure, and the resultant disabling renal 
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osteodystrophy (Silver and Naveh-Many, 1994). Slatopolsky and 
Bricker (1973) and later Lopez-Hiker ^  al. (1990) showed, in 
dogs with experimental chronic renal failure, that dietairy 
phosphorus restriction prevented SHPT. Clinical studies have 
demonstrated that phosphorus restrictions in patients with 
chronic renal insufficiency were effective in preventing the 
increase in serum PTH levels (Portale ^  , 1984; Lucas ^  
al.. 1986). But the mechanism of this effect was not clear, 
although at least part of it was considered to be due to 
changes in serum l,25-(OH)2D3 concentrations. Portale et al. 
(1984) performed metabolic studies in children with moderate 
renal insufficiency and showed that with normal dietary 
phosphorus there was a decrease in serum l,25-(OH)2D3 and an 
increase in serum PTH levels, which were prevented by 
restriction of dietary phosphorus and amplified by 
supplementation with phosphorus. Furthermore, they showed that 
in normal men, phosphorus was a physiological regulator of 
serum l,25-(OH)2D3 levels. It was therefore, assumed that 
phosphorus retention, which occurs even in early renal 
failure, was an important factor in the pathogenesis of the 
SHPT of chronic renal failure by virtue of its effect on serum 
1,25-(0H)2D3 levels and its direct reduction of serum calcium 
by formation of calcium phosphate in the serum, which is then 
deposited in bone and soft tissues (Silver and Naveh-Many, 
1994) . 
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It is evident that low levels of plasma l,25-(OH)2D3 also 
lead to hypocalcemia due to a decrease in absorption of 
calcium from the gastrointestinal tract and possibly by its 
contribution to the skeletal resistance to the calcemic action 
of PTH (Olgaard ^  , 1982). However, clinical studies in 
patients with chronic renal failure have shown that a low 
phosphorus diet prevented an increase in PTH levels without an 
increase in serum l,25-(OH)2D3 levels (Lucas ^  a^.., 1986). 
The occurrence of renal SHPT and hence uremia was shown by 
higher values of plasma creatinine in all rats on high 
phosphorus diets. This conditions might result from the 
concerted actions of reduced renal cell mass and high dietary 
phosphorus which lowered plasma 1,25-(OH) 2D3. 
The increasing levels of plasma creatinine with high 
dietary phosphorus obtained in this study were in agreement 
with other findings reported. Both sham and nephrectomized 
rats fed high dietary phosphorus had more plasma creatinine as 
compared to the control rats fed low dietary phosphorus. Thus, 
in this study plasma l,25-(OH)2D3 levels varied inversely 
proportional to plasma creatinine, suggesting that in advanced 
renal insufficiency the reduced renal tissue mass is a major 
determinant of l,25-(OH)2D3 synthesis and/or secretion. Thus, 
it was suggested that in advanced renal failure, the 
significant decrease in renal mass may not allow dietary 
phosphorus restriction to increase 1,25-{0H)2D3 synthesis 
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(Lopez-Hilker ^  al•, 1990). However, Nagode ^  (1992) 
reported that there was a decrease of plasma creatinine after 
1,25-(0H)2D3 therapy. 
In this experiment with rats, some of the vitamin D 
analogs appear to have some therapeutic potentials for SHPT. A 
reduction in blood phosphate and PTH concentration and an 
increase in blood calcium are positive responses needed in 
SHPT. However, more intensive work would be required to 
determine their effective doses and confirmation before they 
are used for human therapies. Patients of SHPT are more likely 
suffer from damages caused by phosphate overload on the kidney 
tubules than the reduction of renal cell mass. Thus, care must 
be given to the levels of dietary phosphorus intake. 
tPO, •i-Ca ++ 
tPTH + 1 
HP 
>1.1,25-(0H)2D3-5^ 
tCreatinine 4'P04— 
C>B>A 
RENAL FAILURE 
7 
tCa++ 
+t 
A>C>B 
A=B>C 
+T 
iPTH 
B>A>C 
4 
tl,25-(OH)2D3 
CD 
VO 
>l'Creatinine 
A>C>B 
Figure 12. Summarized effect of high phosphorus diet (HP) and the treatment by vitamin D 
analogs during renal failure. A= 1,25-(OH)2D3; B= 1,25-(0H)2D2 '• C= 
1,25,28-(OH) 3D2; - = Decrease; + = Increase. 
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SUMMARY AND CONCLUSIONS 
Plasma phosphate retention and reduction of renal 1,25-
(OlDjDa are the major factors that cause SHPT. 
1. Sham and nephrectomized rats fed high phosphorus diets 
lost 9.50 and 24.72%, respectively, of their initial body 
weights. 
2. Plasma phosphate increased substantially as dietary 
phosphorus increased and the application of vitamin D 
analogs did lower the levels of plasma phosphate. 
3. Treatments by the vitamin D analogs raised the level of 
plasma calcium. 
4. High plasma phosphate has more significant impact on 1,25-
(OH) 2D3 production than the reduction of renal cell mass. 
5. Treatments by the vitamin D analogs did lower the levels 
of plasma PTH. 
6. Among the vitamin D analogs, l,25-(OH)2D3 was most likely 
appeared to be superior because of reduction of plasma 
phosphate, PTH and creatinine and improved plasma calcium 
and 1, 25-(OH) 2D3. 
7. There was an inverse relationship between plasma 
creatinine and plasma levels of 1,25-(OH) 2D3. 
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APPENDIX A 
FEEDING HIGH PHOSPHORUS DIETS SUPPRESSES PLASMA 
1,25-DIHYDROXYVITAMIN D3 PRODUCTION VIA RETENTION 
PLASMA PHOSPHATE IN UNILATERALLY NEPHRECTOMIZED RATS 
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ABSTRACT 
Secondary hyperparathyroidism (SHPT) is a complication of 
chronic renal failure. The two major pathogenic mechanisms 
responsible for the development of SHPT in advanced renal 
insufficiency are phosphorus retention and low levels of 1,25-
dihydroxyvitamin D3 [1,25-(OH)2D3]. Therefore, feeding of 
nephrectomized rats (reduced renal cell mass) with increasing 
levels of dietary phosphorus subsequently enhances plasma 
parathyroid hormone (PTE) and depresses plasma 1,25-(OH) 2D3. In 
this study, 40 rats (20 normal and 20 nephrectomized) were fed 
increasing levels of phosphorus in the diet. The Ca/P % in the 
diets were 0.47/0.68, 0.36/2.55, 0.35/2.99, and 0.47/4.00 on 
an as fed basis. Blood samples were collected after 1®*^ , 2""^ , 
and 3^^^^ months of feeding the diets for the control rats, 
whereas it was only after the l®*" and 2""^ months feeding for the 
nephrectomized rats. Plasma phosphate increased for both 
groups. But declined after the 2"*^ month for the nephrectomized 
rats. Plasma calcium also increased for both groups for the 1®*^ 
month but declined the 2""^ month for the nephrectomized rats. 
However, the month's plasma calcium was found to be lower 
than the 2"*^ month's plasma calcium for the control rats. 
Plasma 1,25-(0H)2D3 was found to be declining all the way 
through the months for both groups. However, the rate of 
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decline was higher in the nephrectomized rats. Plasma 
creatinine was found to be higher for the nephrectomized rats 
as compared to the control rats. 
Although a uniform pattern of the data did not occur, 
increasing phosphorus in the diet depressed the plasma 1,25-
(OlDjDa. Furthermore, increasing phosphorus in the diet 
elevated plasma phosphate significantly. However, the 
declining trend of plasma calcium and phosphate, particularly 
in the nephrectomized rats after the 1®*^ month, must be 
verified by further research. Equally important is the 
duration of the study. The longer the nephrectomized rats 
stayed on the diets, the less appetite they had for the diets 
and hence the more body weight they lost. 
INTRODUCTION 
Renal insufficiency is characterized by several 
alterations in mineral homeostasis (Lopez-Hilker ^  , 
1990). Secondary hyperparathyroidism (SHPT) is present even in 
the early stages of renal insufficiency and leads to the 
development of renal osteodystrophy (Slatopolsky and Bricker, 
1973; Wilson ^  al./ 1985; Tessitore ^  a^., 1987; Pitts et 
al.. 1988; Kubrusly ^  al., 1993). 
The two major pathogenic mechanisms responsible for the 
development of SHPT in advanced renal insufficiency are 
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phosphorus retention and low levels of 1,25-dihydroxyvitaniin 
D3 [1,25-{0H)2D3] (Lopez-Hilker et al. . 1990). 
Hyperphosphatemia results in hypocalcemia by several 
possible mechanisms, including inhibition of the activity of 
the renal enzyme la-hydroxylase (la-OHase) which is already 
limited by the decrease in renal mass (Lopez-Hilker ^  al., 
1990). Therefore, low levels of l,25-(OH)2D3 lead to decreased 
calcium transport by the gastrointestinal tract (Coburn ^  
al. . 1973), altered synthesis and secretion (Slatopolsky et 
al. . 1984; Silver ^  , 1985; Chan ^  a^,. / 1986) of 
parathyroid hormone (PTH) and possibly skeletal resistance to 
the calcemic actions of PTH (Lopez-Hilker et al., 1990). 
1,25-(0H)2D3 is the metabolite of vitamin D currently 
considered to be the most biologically active with respect to 
bone resorption and intestinal absorption of calcium and 
phosphorus (Portale ^  al., 1984). 
The synthesis of l,25-(OH)2D3 from its endogenous 
precursor, 25-hydroxyvitamin D3 (25-OHD3) , occurs in 
mitochondria of the proximal renal tubule and is catalyzed by 
the enzyme la-OHase (Kawashima ^  , 1981) . In patients with 
severe (Chesney et al., 1982; Cheung ^  al., 1983) and 
moderate (Portale ^  , 1982) reductions in the plasma 
concentrations of 1,25-(OH) jD presumably reflect a reduction 
in the renal synthesis of 1,25-(0H)2D3 in the proximal tubule 
of the kidney (Lopez-Hilker ^  al., 1990) . 
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In patients with renal insufficiency, reduction in 1,25-
(OlDzDj reflects a reduced amount of la-OHase, but could also 
reflect a reversible suppression of the activity of the 
remaining enzyme (Haussler and McCain, 1977; Van Stone ^  al.. 
1977) even though the activity of this enzyme is normally 
stimulated by PTH (Nomnan ^  al., 1980; Lopez-Hilker, 1984). 
Reports indicate that the activity of la-OHase and 
apparent production of l,25-(OH)2D3 are not principally 
determined by PTH, but rather by a suppressive effect of 
inorganic phosporus (Broadus ^  al., 1983). 
Support for the major role of phosphorus retention has 
been provided by several investigators who have shown that 
decreasing the amount of phosphorus in the diet in proportion 
to the fall in glomerular filtration rate (GFR) prevents SHPT 
(Slatopolsky et , 1972) or ameliorates (Kaplan ^  al., 
1979; Portale ^  , 1984; Llach and Massry, 1985) . The 
mechanism of this effect remains unclear (Lopez-Hilker ^  al.. 
1990) . 
In normal humans (Portale et , 1986) and patients with 
moderate renal insufficiency (Portale ^  al., 1984; Llach and 
Massry, 1985), restriction of dietary phosphorus increases the 
production of 1,25-(OH) 2D3, thus, decreasing the levels of 
immunoreactive PTH (iPTH). However, this mechanism may not be 
operative in advanced renal insufficiency, because the 
decrease in renal mass may severely limit the production of 
118 
1,25-(0H)2D3 (Lopez-Hilker ^  al., 1990). 
Therefore, the present study was designed to investigate 
if plasma phosphate retention could be associated with reduced 
plasma l,25-(OH)2D3 production in unilaterally nephrectomized 
rats used as SHPT model. 
Materials and Methods 
Animals 
Forty male Sprague-Dawley-Harlan 60-day-old rats weighing 
450 ± 50 gm were used in this study. All rats were housed 
individually and fed a standard laboratory rat chow until the 
beginning of the experiment. 
When the adaptation period was over the rats were randomly 
divided into two groups, control (20 rats) and treatment (20 
rats) and each group again divided into four subgroups. Then, 
they were assigned to synthetic diets having different 
combinations of calcium and phosphorus as indicated below. 
Water was always offered a^ libitum. 
The treatment rats were ventrodorsally shaved and 
anesthetized with intraperitoneal injection of 60 mg/kg 
Ketamine and their entire left kidney was removed (Lieuallen 
et al., 1990). Following the removal of the kidneys, the rats 
were maintained on standard laboratory rat chow for seven days 
of recovery. They were housed and maintained according to 
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Federal regulation regarding animal care. 
Diets 
A low calcium diet (0.02% calcium) was purchased from 
Teklad, Madison, WI and fortified with different levels of 
calcium and phosphorus using either calcium phosphate 
(CaHPO^) , calcium carbonate (CaCOj) or sodium phosphate 
(Na2HP04) (laboratory grade, Fisher Scientific, Fairlawn, NJ) 
as source materials. The levels of vitamin D remained 
unaltered. Thus, there were four diets (Dl, D2, D3 and D4) 
assigned to each control and treatment subgroups as below. 
Calcium and phosphorus levels were expressed on an as fed 
basis. 
Diet Ca (%) P (%) Ca:P Ratio 
Dl 0.47 0.68 1:1.45 
D2 0.36 2.55 1:7.08 
D3 0.35 2.92 1:8.34 
D4 0.46 4,00 1:8.70 
Body weight measurements 
Body weight measurements (gm) were made for each rat at 
the beginning and at the end of the experiment. Body weight 
changes (%) were calculated from the differences between the 
beginning and end body weights expressed as a percentage. 
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Feed intake 
Daily feed intake (gm/day) was measured by offering the 
rats known amounts of the diets in aluminium dishes (purchased 
from Wal-Mart store). Every day the left overs were weighed 
and subtracted the diets offered upon which the daily intakes 
were found by differences. 
Urine collection 
Daily urine was collected from each rat in a metabolic 
cage. Then, urine calcium (mg/day), phosphorus (mg/day) and 
creatinine (mg/day) were determined according to Perkin-Elmer 
Corp (1965), Parekh and Jung (1970), and Chasson ^  al. 
(1961), respectively. 
Blood sample collection and plasma analvses 
Blood samples (1.5 - 2.0 ml) were collected from the 
external jugular vein except the final sampling. 
At the end of third and second months of feeding (control 
and treatment, respectively), all rats were anesthetized under 
COj-Oj (50%:50% vol/vol) and decapitated. Blood sample was 
collected in heparinized tubes and centrifuged for 5 minutes 
at 2300 rpm. Plasma was aspirated and refrigerated in the deep 
freezer until analysis. 
Plasma analyses were made for calcium (Perkin-Elmer corp., 
1965), phosphorus (Parekh and Jung, 1970), l,25-(OH)2D3 
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(Reinhardt ^  al., 1984) and creatinine (Chasson ^  al.. 
1961) . 
Statistical analysis 
One way anlysis of variance (ANOVA) was used to test the 
hypothsis that the means difference between the control and 
unilaterally nephrectomized rats were the same. Results were 
considered significant when probability was less than 0.05 
(Snedecor and Cochran, 1980). 
RESULTS 
The mean of feed intake (gm/day) of control and 
nephrectomized rats is presented in Table 3. Feed intake was 
decreased as the level of phosphorus increased in the diets. 
But there was no significant change among the subgroups except 
the nephrectomized subgroup on 0.46/4.00 Ca/P percentage'which 
showed to consume more feed (18.47 ± 0.71) than the other 
subgroups. This higher value was attributed to wastages and 
the real consumption was much less than that. 
The mean plasma phosphate concentration (mg/dl) for the 
control and nephrectomized rats for the l®*^, 2"'^, and 3^"^ months 
is shown in Figure 13. The mean plasma phosphate of 
nephrectomized rats was higher than the control rats during 
the 1®*^ month, however, it declined during the 2"^ month. As the 
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level of phosphorus increased in the diets, the plasma 
phosphate increased. 
The mean plasma calcium concentration (mg/dl) for the 
control and nephrectomized rats fed increasing levels of 
phosphorus in the diet for 3 and 2 consecutive months, 
respectively, is presented in Figure 14. During the 1®*" month 
there was no difference between the control and nephrectomized 
rats, although, a trend has been observed that plasma calcium 
declined as diet phosphorus level increased in the diets. In 
the second month, plasma calcium was depressed in the 
nephrectomized rats, although there was a slight increase in 
the control rats. In the third month, plasma calcium in 
nephrectomized rats was found to be significantly lower than 
the control rats. 
The mean plasma l,25-(OH)2D3 (pg/ml) for the control and 
nephrectomized rats fed increasing levels of phosphorus in 
diets is presented in Figure 15. There was a progressive 
decline in plasma l,25-(OH)2D3 concentration in both the 
control and the nephrectomized rats throughout the study 
period. However, the values observed for the nephrectomized 
rats were much lower than the control rats throughout the 
study period. Therefore, increasing levels of phosphorus in 
diets, together with reduced renal cell mass, reduced plasma 
1,25-(0H)2D3 in the nephrectomized rats. 
The mean plasma creatinine (mg/dl) of control and 
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nephrectomized rats fed increasing levels of phosphorus in 
diets is presented in Figure 16. Plasma creatinine of 
nephrectomized rats was higher than the control rats during 
the first and second months of the study period. 
The mean urine volume (ml/day), urine phosphorus (mg/day), 
urine calcium (mg/day), and urine creatinine (mg/day) are 
presented in Figures 17, 18, 19, and 20, respectively. The 
urine volume of nephrectomized rats was found to be much 
higher than the control rats and increased as the level of 
phosphorus increased in the diets. Urine phosphorus also 
showed an increasing trend as the level of phosphorus 
increased in the diets. Urine calcium did not show much 
difference between the control and nephrectomized rats. But., 
urine creatinine of nephrectomized rats was increased as the 
level of phosphorus increased in diets. 
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Table 2. Mean body weight changes (%) of two groups of rats 
(control and nephrectomized) fed increasing 
levels of phosphorus in the diets 
Ca/P (%) Control* Nephrectomized* P value 
0.47/0.68 89.22 ± 6.24 28.62 ± 4.20 P<0.001 
0.36/2.55 31.00 ± 5.32 - 5.77 ± 8.36 P<0.05 
0,35/2.92 22.73 ± 4.42 - 1.68 ± 7.69 ns 
0.46/4,00 24.57 ± 14.09 - 20,44 ± 0,46 P<0.05 
+ = gain in body weight, 
- = loss in body weight. 
ns = not significant. 
* = mean ± SEM (standard error of mean). 
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Table 3. Mean feed intake (gm/day) of two groups of rats 
(control and nephrectomized) fed increasing levels of 
phosphorus in the diets. 
Ca/P (%) Control* Nephrectomized* P value 
0.47/0.68 
0.36/2.55 
0.35/2.92 
0.46/4.00 
22.93 ± 0.65 
17.10 ± 3.31 
14.27 ± 2.00 
13.47 ± 2.70 
22.22+3.12 ns 
17.17 ± 2.56 ns 
8.82 ± 1.30 ns 
18.47 ± 0,71 ns 
* = mean ± SEM. 
ns = not significant 
Figure 13. Mean plasma phosphate (mg/dl) of two groups of 
rats control and nephrectomized) fed increasing 
levels of phosphorus in the diets. Plasma 
phosphate was deteirmined at the l®"", 2"*^ , and 3"^  ^
months of feeding the diets. The 
calcium/phosphorus percentages were 0.47/0.68, 
0.36/2.55, 0.35/2.92, and 0.46/4.00 on an as fed 
basis. Results are expressed as mean ± SEM 
{standard error of mean). Insert is plasma 
phosphate from normal rats fed laboratory rat 
chow for three months. 
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Figure 14. Mean plasma calcium (mg/dl) of two groups (control 
and nephrectomized) of rats fed increasing levels 
of phosphorus in the diets. Plasma calcium was 
determined at 1®*^, 2""^, and months of feeding the 
diets. The calcium/phosphorus percentages were 
0.47/0.68, 0.36/2.55, 0.35/2.92, and 0.46/4.00 on 
an as fed basis. Results are expressed as mean ± 
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Figure 15. Mean plasma 1,25-{0H)2D3 (pg/ml) of two groups 
(control and nephrectomized) of rats fed 
increasing levels of phosphorus in the diets. 
Plasma l,25-(OH)2D3 was determined at 1®*^, 2°^' and 
2''^ months of feeding the diets. The 
calcium/phosphorus percentages were 0.47/0.68, 
0.36/2.55, 0.35/2.92, and 0.46/4.00 on an as fed 
basis. Results are expressed as mean ± SEM. 
Insert is plasma l,25-(OH)2D3 from normal rats 
fed laboratory rat chow for three months. 
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Figure 16. Mean plasma creatinine (mg/dl) of two groups 
(control and nephrectomized) of rats fed 
increasing levels of phosphorus in the diets. 
Plasma creatinine was determined at 1°*=, 2"^, and 
3^"^ months of feeding the diets. The 
calcium/phosphorus percentages were 0.47/0.68, 
0.36/2.55, 0.35/2.92, and 0.46/4.00 on an as fed 
basis. Results are expressed as mean ± SEM. 
Insert is plasma creatinine from normal rats fed 
laboratory rat chow for three months. 
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Figure 17. Mean urine volume (ml/day) of two groups (control 
and nephrectomized) rat fed increasing levels of 
phosphorus in the diets. Urine volume was 
collected from two rats from each groups for 
seven days. The calcium/phosphorus percentages 
were 0.47/0.68, 0.36/2.55, 0,35/2.92, and 
0.46/4.00 on an as fed basis. 
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Figure 18. Mean urine phosphrus (mg/day) of two groups 
(control and nephrectomized) rats fed increasing 
levels of phosphorus in the diets. Urine 
phosphorus was determined from urine of two rats 
from each groups collected for seven days. The 
calcium/phosphorus percentages were 0.47/0.68, 
0.36/2.55, 0.35/2.92, and 0.46/4.00 on an as fed 
basis. 
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Figure 19. Mean urine calcium (mg/day) of two groups 
(control and nephrectomized) of rats fed 
increasing levels of phospohrus in the diets. 
Urine calcium was determined from urine of two 
rats from each groups collected for seven days. 
The calcium/phosphorus percentages were 
0.47/0.68, 0.36/2.55, 0.35/2.92, and 0.46/4.00 on 
an as fed basis. 
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Figure 20. Mean urine creatinine (mg/day) of two gropus 
(control and nephrectoraized) of rats fed 
increasing levels of phosphorus in the diets. 
Urine creatinine was determined from urine of two 
rats from each groups collected for seven days. 
The calcium/phosphorus percentages were 
0.47/0.68, 0.36/2.55, 0.35/2.92, and 0.46/4.00 on 
an as fed basis. 
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DISCUSSION 
Feeding increasing levels of phosphorus in the diets to 
control (normal) and nephrectomized rats showed that the feed 
intake was progressively decreased as the dietary phosphorus 
level increased. But it seems likely that the control rats ate 
more than the nephrectomized rats. There was a wastage of 
diets on both sides, however, the degree of wastage was higher 
in the nephrectomized rats. Nephrectomized rats showed to tear 
the aluminium dishes (used for feeding) and did not have 
appetite for the diets. Moreover, they had a greater tendency 
to drink more water as compared to the control rats. Becuase 
of these factors and others, nephrectomized rats were 
emaciated and lost much of their body weights (as much as 60% 
in some cases) during the study. Consequently, most of them 
died and the study was terminated at the end of the second 
month. Therefore, the study must have been limited to a 
duration of one month where data should have been collected 
either every 5 or 10 days apart. But this was not done in this 
study. Thus, keeping the rats on the diets for the duration of 
3 months did not contribute much either in information 
collection nor improvement of the data. 
Feeding increasing levels of phosphorus in the diets to 
control and nephrectomized rats progressively decreased feed 
intake (data not shown) as the phosphorus levels in the diets 
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increased. Particularly, nephrectomized rats did not have 
appetite for the diets and they spent most of their time 
around waterers. Because of these factors and others, they 
were emaciated and lost much of their body weight (as much as 
60%) (data not shown) during the study. Consequently, most of 
them died and the study was terminated at the end of the 
second month. Therefore, the study should have been limited to 
a duration of one month where data should have been collected 
either every 5 or 10 days apart. But this was not done in this 
study. Thus, keeping the rats on the diets for 3 months did 
not contribute much either in information collection nor 
improvement of the data. 
The present study demonstrated that feeding increasing 
levels of phosphorus in the diets reduced the plasma 1,25-
(OH) 2D3 both in the control and nephrectomized rats. Several 
reports indicate that restriction of dietary phosphorus can 
induce an increase in the serum concentration of 1,25-(OH)jD 
in normal men and women (Gray ^  al., 1977; Insogna ^  al.. 
1983; Lufkin et a^.. , 1983; Maierhofer ^  , 1984) and in 
children with moderate renal insufficiency (Portale ^  , 
1986). Coversely, supplementation decreases serum 
concentration of 1,25-(OH) jD from supernormal to normal levels 
(Portale ^  al., 1986). It has been inferred that these 
phosphorus-induced changes in serum concentration of 1,25-
(OIDjD reflect changes in the rate of its renal production. 
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because in the chick and rat, restriction of dietary 
phosphorus can increase both the activity of renal la-OHase 
(Baxter and DeLuca, 1976) and the synthetic rate of 1,25-
(OlDjDa (Gray and Napoli, 1983; Lobaugh and Drezner, 1983) when 
measured in vitro (Portale ^  al., 1986). Furthermore, when 
phosphorus was restricted and then supplemented, the observed 
increase and decrease in serum concentration of 1,25-(OH) jD 
was associated with an increase and decrease, respectively in 
the production rate of the hormone, but not with a significant 
change in its metabolic clearance rate (Portale et al., 1986). 
Thus, the findings of Portale ^  (1986) demonstrated that 
in healthy men, changes in production rate of 1,25-(OH) jD 
account entirely for the phosphorus-induced changes in serum 
concentration of this hormone as opposed to increased turnover 
of hormone. 
During chronic renal failure, the number of functioning 
renal tubules progressively decreases (Nagode et , 1992). 
Because of the loss of the tubular cells that produce 1,25-
(0H)2D, its synthesis becomes limited. 
1,25-(OH) 2© formation is also affected by the powerful 
inhibition of the la-hydroxylation of 25-hydroxyvitamin D (25-
OHD) by high levels of blood phosphorus (Slatopolsky ^  al., 
1972; Slatopolsky and Bricker, 1973; Feinfeld and Sherwood, 
1988) . 
As serum phosphorus levels increase following reduced 
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glomerular filtration rates (GFRs), serum phosphorus 
concentrations are achieved that block synthesis of 1,25-
(OlDgDj (Nagode et , 1992) . 
The importance of the inhibitory effect of phosphorus on 
canine 1,25-(OH) aD has been shown previously by Nagode and 
Steinmeyer (1979). It is revealed by the more regular drop in 
1,25-(OH) jD with increasing levels of serum phosphorus. 
Although, high levels of inorganic phosphorus (P^) inhibit 
1,25-(OH) 2D, lowering serum Pi below normal does not raise 
serum 1,25-(OH) jD above normal in the dog (Nagode and 
Steinmeyer, 1982) . 
The following statments could be summarized from this 
study: 
1. Feed intake declined in both control and nephrectomized 
rats as the level of phosphorus increased in the diets. 
2. Increasing dietary phosphorus increased plasma phosphate 
both in the control and nephrectomized rats. 
3. Plasma calcium of control rats was higher than in the 
nephrectomized rats. 
4. Plasma l,25-(OH)2D3 progressively declined both in the 
control and nephrectomized rats as the level of 
phosphorus increased in the diets. 
5. Plasma creatinine of nephrectomized rats was higher than 
the control rats. 
6. Urine volume was higher in the nephrectomized rats and 
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increased as the level of phosphorus increased in the 
diets. Thus, failure to concentrate urine is the first 
sign of renal failure. 
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APPENDIX B 
ASSAYS 
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Extraction cuid Binding Assay of l,25-(OH)2D3 
Extraction of 1. 25-dihvdroxwitamin D, 
1. Pipette 1 ml of sample into 12 x 75 test tube. If using 
less than 1 ml bring volume to 1 ml with saline. 
2. Add 50 fil of radioactivity (1000 cpm/50 ml) to each tube 
and to a vial for total count (TCT). Voretx and let sit for 
5 minutes. 
3. Add 1 ml of actonitrile (ACN) (with the drop of NH4OH/I 
liter) to each tube and vortex for 30 seconds on the multi-
tube vortexer. 
4. Centrifuge tubes for 15 minutes at 2300 rpm . 
5. While tubes are centrifuging, add 500 /il 0.4 M K2HPO4 buffer 
to another set of 12 x 75 tubes. Set up (Incstar) C180H 
cartridges in the black rack. Label 13 x 100 test tubes to 
collect into. 
6. Wash the cartridges with the usual order of solvents: 
a. 5 ml Hexane and suction. 
b. 5 ml Chloroform and suction. 
c. 5 ml of Methanol and suction. 
7. After washing add 5 ml of distilled water (dd HjO) to 
each cartridge and leave on until the samples are out of 
centrifuge. 
8. When samples are finished centrifuging, transfer the 
supernatant into the approperiate tube containing the 
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phosphate buffer and vortex. 
9. Apply sample to cartridge with a pasteure pipette after 
suctioning off the dd HjO and then wash as follows: 
a. 5 ml of dd HjO and suction 
b. 5 ml of 70:30 (MeOH/HjO) and suction 
c. 5 ml of 90:10 (Hex/MeClj) and suction 
d. 5 ml of 99:1 (Hex/Isop) and then suction 
e. 5 ml of 95:5 (Hex/Isop) and collect** 
10. Samples are now ready for binding assay. When ready to 
collect move the top of the rack from waste to collect and 
place your tubes under the approperiate spouts. 
Binding asaav of 1.25-(OHKD^ 
1. Dry down 95:5 Hex/Isop fraction from silica Sep-pak. 
2. Reconstitute a frozen thymus pellet in 7 ml of thymus 
buffer and then add the specified amount of buffer for 
that batch of thymus. 
3. Add 100 /jlI reagent alcohol (Fisher brand) to each tube. 
Cork tightly. Vortex. Let sit 3 0 minutes in ethyl 
alcohol (EtOH) bath. 
4. Label duplicat 12 x 75 tubes for each sample and 
standards. Also label a set of scintillation vials for 
the recoveries of the samples (r^, rj,...) and label 
duplicate scintillation vials for samples and standards. 
5. Add 500 fil of thymus mixture to each tube. 
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6. Add the standards (0,1/2,4,8,16,32,64 pg and NSB) to the 
appropriate tubes. 
7. After the samples have set for 30 minutes in ethanol 
bath, pipette two 25 /xl aliquots, for each sample, into 
the two tubes in the ice water bath and one 25 /xl 
aliquot into a scintillation vial for recovery. 
8. Vortex, keeping on ice. 
9. Incubate in shaking water bath at 25° C for 45 minutes. 
At this time you can get the magic charcoal stirring on 
the cold stir plate. 
10. Place samples in ice water bath for 5 minutes and then 
add 5000 cpm [^H] 1,25 (OH)2D3/20 /il. 
11. Vortex and put back in shaking water bath at 25°C for 30 
minutes. 
12. Place samples in ice water bath and add 200 /xl of 
charcoal. Charcoal should be stirring for at least one 
hour before use and should be kept cold. 
13. Vortex and let tubes sit in ice water for 15 minutes (or 
let them sit in cooler). Vortex once more and centrifuge 
at 2300 rpm for 10 minutes. 
14. Pipette 500 /xl from each sample into scintillation 
vials. Add 5 ml cocktail. 
15. Count radioactivity in the scintillation counter by 
putting the right program. 
155 
Standard curve of 1.25-(OH)^D, 
1. Check 1,25 (OH)2D3 cold standard on the spectrophotometer. 
2. Make 4 ml of the NSB tube which is at a concentration of 
800 pg/25 fil (32 pg/ptl) . 
32 -pg/fil X 4000 fil = 128,000 pg = 128 ng 
128 ng/concentration of standard = /zl of standard 
that needed and bring the volume up to 4 ml with reagent 
alcohol. 
3. Make 4 ml of stock standard at a concentration of 640 
pg/25 fil (25.6 pg//xl) . 
25.6 pg//xl X 4000 fil = 102,400 pg = 102.4 ng 
102.4 ng/concentration of standard = fil of stndard 
that needed and bring the volume up to 4 ml with reagent 
alcohol. 
4. Make a 1:10 dilution of this 640 pg/25 /xl'standard (400 
^1 in 3600 fil of reagent alcohol) to get to the 64 pg/25 
fil standard that would be the final standard of the 
curve. 
5. Make 2:1 serial dilution down from this 64 pg/25 fil 
standard for the rest of the curve (i.e., 32,16,8,4, 2&1 
pg/25 fil) so that it could be ended up with 4 ml in the 
1 pg/25 fil standard and 2 ml in all the rest. 
6. Use the Rainin pipette to do the serial dilutions. 
7. Blow nitrogen over all the standards when finished and 
cork wrap parafilm around the cork and store in the 
freezer. 
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Phosphorus Assay 
Reagents 
All reagents are prepared from analytical grade chemicals 
using deionized distilled water. 
1. TCA: 10% 
2. Sulfuric acid solution: Dilute 30 ml of concentrated 
sulfuric acid up to 100 ml with water. Add acid to water. 
3. Molbdic acid solution: Dissolve 5 g of ammonium-molybdate 
(NH4) 6Mo,024H20) in 100 ml of sulfuric acid solution. 
4. Molybdic-TCA reagent: Mix 1 volume of molybdic acid 
solution with 2 volumes of 10% TCA solution. 
5. p-Phenylenediamine reagent: Dissolve 0.5 g of p-
phenylenediamine dihydrochloride in 100 ml of 5% sodium 
meta bisulfite (NajSaOg) solution. 
6. Phosphorus standard: (a) stock solution: Dissolve 0.6589 g 
of pure, well dried mono potassium phosphate (KH2PO4) in 10 
ml of 10 N sulfuric acid. Q.S. to 1 liter in volumetric 
flask. Yields 15 mg inorganic phosphorus/100 ml. Standards 
used are 15, 10, 7, 5, 3, & 1. 
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Phosphorus assay in plasma and bone 
Precipitation 
1. Pipette 25 /xl serum (avoid hemolysis) sample into a 
microtiter plate. NB: for bone sample use a 1:21 dilution 
with water. 
2. Add 200 fil of molybdic-TCA reagent. Do the same for 
standards and blank using standard and water respectivly in 
place of serum. 
3. Vortex and let stand for 5 minutes. Centrifuge for 5 
minutes for 5 minutes. 
Color Development 
1. Transfer 50 /il supernatant into a new microtiter plate and 
add 200 /il p-phenylenediamine reagent. Vortex. 
2. Let stand for 20 minutes. 
3. Read microplate reader using program "Phosphorus Assay". 
4. For bone phosphorus, spin at end of 20 minutes and ransfer 
to new plate before reading. 
Phosphorus assav in the urine 
Do 1/5 and 1/25 dilutions of urine in water (usually one of 
these dilutions will be on the standard curve). 
1. Pipette 25 /il of standard or sample into microtiter 
plate well and add 200 /il of molybdic acid-TCA reagent. 
2. Shake for 5 minutes then centrifuge for 5 minutes at 
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2300 rpm. 
3. Transfer 50 fil supernatant from plate 1 into 
corresponding well of plate 2. 
4. Add 200 fil p-phenylenediamine reagent. Shake plate. 
5. Incubatefor 20 minutes at room temperature. 
6. Read on microplate reader using "Phosphorus Assay". 
CalciTJin Assay 
Machine set-up 
1. Turn on compresed air tank 10 minutes before wish to read 
samples. 
2. Enter the settings on the machine as follows: 
setting for the AA: Lamp =# 1 at 15 ma program # 1. 
Setting for the P.E. 5000 Automatic Burner Control: 
Fuel = 49, Air =59. To enter the settings, enter 
The number and then press the approperiate button. 
3. Allow the machine to warm up for at least 5 minutes. 
4. After machine warmed up for at least 5 minutes, turn 
the acetylene tank on and then push the flame on/off 
button on the burner control. It may be necessary to push 
this button 2 or 3 times before the flame actually 
ignites. 
5. Allow the machine to warm up for an additional 5 minutes 
with the flame on. Make sure there is sufficient 
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distilled water in the container with the sipper tube. 
6. After the additional five minutes check to see that the 
energy level is in the 70's before an attempt to read 
samples. 
7. Check the printer to make sure there is adequate paper in 
there to complete the run. 
Preparations of samples 
1. Plasma samples are usually diluted 1 to 41. Pipette 100 fil 
of sample into 17 x 100 mm falcon tube and dilute with 4 ml 
of 0.1% lanthanum oxide working solution and vortex. Urine 
samples are usually diluted 1 to 41 first using 0.5% 
lanthanum oxide working solution and then diluted 
additionally from this point if they need to be. 
2. Standards are pipetted just like the samples (1/41). The 0 
standard is just straight LajOa. Other standards include 5, 
10 and 15 mg%. 
3. Samples and standards are usually run in duplicate. 
4. Stock lanthanum oxide solution: 
58.64 gm/liter LazOj (Sigma brand). 
250 ml Nitric acid (HNO3) . 
Bring up to 1 liter with deionized water. 
5. Working lanthanum oxide solution: 
a. for plasma: 20 ml stock solution/liter (0.1%). 
b. for urine: 100 ml stock solution/liter (0.5%) 
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6. Standard Preparation: 
Use Fisher brand (Certified Atomic Absorption Standard) 
Calcium at a concentration of 1 ml = 1 mg Ca. 
5 mg% = 50 ml/liter 
10 mg% = 100 ml/xiter 
15 mg% = 150 ml/liter 
Dilute up to 1 liter with 0.1 N HNO3. 
Running standards and samples 
1. Zero the machine by pressing all the buttons on the left of 
the calibration set (AZ, SI, S2, S3) once going and down 
once coming back up the line. 
2. Place sipper tube into the 0 standard and press the AZ 
button twice. 
3. Place sipper tube into the 5 mg% standard and punch in 
the numerical key pad and then punch the SI button twice. 
Do this step for the 2 standards punching in the 
approperiate number (10.00 or 15.00) and the S2 and S3 
buttons. 
4. Now go back and read the 5 and 10 standards by placing 
the sipper tube into the standard and pressing the read 
button. If the standards come out to be within 0.2 mg% of 
the reading it should be then ready to continue with 
samples.If not then see below under troubles shooting. 
5. To get values to print out push the print button to the 
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left of the machine (on the top). The printer will start at 
number 1 and number each sample read in order from this 
point. To number each sample differently, punch in the 
number first on the numeric key pad and then press before 
reading sample. 
6. Place sipper tube into the sample and punch the read 
button. 
7. In doing several samples at once it is important to make 
up a sample that can be run as an internal standard after 
every 10 samples to make sure that the machine is not 
drifting. If drift is encountered (ie., the value of this 
sample changes by more than 0.2 mg% over the course of the 
reading), then it is necessary to go back and rezero the 
machine and start over again. 
Creatinine Assay in Plasma cuid Urine 
Reagents 
Creatinine kit: Sigma catalog # 55-A or Picric acid 
[ (OjN) jCgHgOH or 2,4,6 trinitrophenol] 0.04M 
(9.16 gm anhydrous or 10.17 gm reagent grade with water) 
NaOH 3 N. 
Stock Creatine 160 mg/ml in 0.1 N HCl. 
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Protocol 
1. Dilute urine samples 1:10 with dd water. 
2. Prepare a standard curve 0, 2.5, 5, 7.5 and 10 mg/ml 
3. Pipette 10 ul of standard in duplicate or triplicate into 
titer plate. Use dd water for blank and 0 standards 
respectively. 
4. Pipette diluted samples into the titer plate in 
duplicates/triplicates. 
At this point if using Creatinine kit from Sigma go to 
step 10 now. 
5. For every 20 ml of 0.04 picric acid to be used add 1 ml of 
3N NaOH and mix. Mix in separate beaker. 
6. Add 200 ml of Alkaline/Picrate mixture to each standard 
and sample well. Vortex. 
7. Let sit at room temperature for 30 minutes. 
8. Read absorbance between 490 and 520 nm. 
9. For plasma creatinine use the same procedure but do not 
dilute. 
10. For every 5 ml of 0.04 M picric acid to be used add 1 ml 
of IN NaOH from kit and mix. Or add 5 ml of 0.6% 
creatinine reagent for every 1 ml of 1 N NaOH. 
11. Add 200 ul the alkaline /picrate solution to each standard 
and sample well. Vortex. 
12. Let sit at room temperature for 30 minutes. 
13. Read absorbance between 490 and 520 nm. 
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Assay of PTH Levels in Rat Serum 
Reagents preparation and storage 
Store the kit at 2-8°C upon receipt. Store the standards 
and controls at -20°C after reconstitution. Prior to use allow 
all reagents to come to room temperature and mix by gentle 
swirling and inversion. 
1. Rat PTH antibody coated beads: 100 polysryrene beads 
(64. diameter) coated with antibody to rat PTH plus 
desiccant. 
2. labeled rat PTH antibody: two vials each containing 
5 ml of labeled anti-rat PTH in 0. 6M phos [hate 
buffered saline with protein stabilizers and 0.1% sodium 
azide. Each vial contains less than 10 /iCi (370 kBq) of 
radioactivity. 
3. Rat PTH standards: six vials containing rat PTH (1-34) 
lyophilized in a protein matrix with 0.1% sodium azide. 
Before use reconstitute the vials with the rat PTH 
concentration of 0 pg/ml with 4.0 ml of deionized water. 
Before use reconstitute the other five vials of 
standards with 2.0 ml of deionized water. Allow the 
vials to sit for approximately 20 minutes with 
occasional gentle swirling and inversion. Assure 
complete reconstitution before use. 
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4. Rat PTH controls I&II: two vials each containing rat PTH 
(1-34) lyophilized in a protein matrix with 0.1% sodium 
azide. Before use reconstitute the controls with 2.0 ml 
of deionized water. Allow the vials to sit for 
approximately 20 minutes with occasional gentle swirling 
and inversion. Assure complete reconstitution before 
use. 
5. Wash concentrate: one bottle containing 3 0 ml of a 30 
fold concentrate. Before use dilute the contents to 900 
ml deionized water and mix well. Upon dilution this 
yields a working solution containing a surfactant in 
O.OIM phosphate buffered saline with 0.05% sodium azide. 
The diluted wash solution should be stored at room temperature 
and is stable until the expiration date on the kit box. 
Other Materials Required 
1. Polystyrene or polypropylene tubes, 12 x 75 mm. 
2. Test tube rack. 
3. Marking pen for labeling tubes. 
4. 2.0 ml and 4.0 ml volumetric pipettes for reconstituting 
standards and controls. 
5. Precision pipettes capable of delivering 100 /xl and 200 
/xl. 
6. Forceps or suitable bead dispenser. 
7. Parafilm or equivalent for covering tubes. 
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8. Repeating dispenser suitable for delivering 2.0 ml. 
9. Aspiration device or suitable bead washer. 
10. Container for storage of of wash solution. 
11. Gamma counter. 
12. Deionized water. 
13. Vortex mixer. 
14. Timer. 
Protocol 
1. Pipette 200 [il of standard, control or sample into 
appropriately labeled tubes. 
2. Pipette 100 111 of labeled rat PTH antibody into all 
tubes. 
3. Vortex all tubes. 
4. Using forcepsor appropriate bead dispenser, and one bead 
to each tube. If using forceps, tilt tube rack to 
approximately a 30 degree angle to prevent splashing. 
Cover tube rack with parafilm or equivalent. 
5. Incubate tubes at room temperature for 18 to 24 hours. 
6. Aspirate the contents of each tube. Wash beads three 
times by dispencing 2.0 ml of wash solution into each 
tube then completely aspirating the contents. 
7. Count each tube in a Gamma counter for one minute and 
record the counts. 
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Calculation of results 
The standard curve is generated using the rat PTH standards 
contained in the kit. Generate the curve as follows: 
1. Calculate the average cptn for each pair of duplicate tubes. 
2. Subtract the average cptn of the 0 pg/ml standard from all 
other average cpms to obtain corrected cptn. 
3. The standard curve is generated by plotting the corrected 
cptn of each standard level on the ordinate against the 
standard concentration on the abscissa using log-log paper. 
Appropriate computer assisted data reduction programs may 
also be used for calculation of rat PTH results. 
4. The rat PTH concentrations of the controls and samples are 
read directly from the curve using their respective 
corrected cpm. Samples having corrected cpms between the 0 
pg/ml standard and next highest standard should be 
calculated by dividing the corrected cpm (unknown) by 
corrected cpm (2"*^ std.) and multiplying by the value of the 
2""^ std. 
